[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1381
1. Kim YM, Ramírez JA, Mick JE, Giebler HA, Yan JP, Nyborg JK: Molecular characterization of the Tax-containing HTLV-1 enhancer complex reveals a prominent role for CREB phosphorylation in Tax transactivation. J Biol Chem; 2007 Jun 29;282(26):18750-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of the Tax-containing HTLV-1 enhancer complex reveals a prominent role for CREB phosphorylation in Tax transactivation.
  • Transcriptional activation of human T-cell leukemia virus type 1 (HTLV-1) is mediated by the viral oncoprotein Tax, which utilizes cellular transcriptional machinery to perform this function.
  • The coactivator CREB-binding protein (CBP)/p300 binds to this promoter-bound ternary complex, which promotes the initiation of HTLV-1 transcription.
  • Consonant with a fundamental role for CREB phosphorylation in Tax recruitment to the complex, we found that CREB is highly phosphorylated in a panel of HTLV-1-infected human T-cell lines.
  • Because pCREB has been implicated in leukemogenesis, enhancement of CREB phosphorylation by the virus may play a role in the etiology of adult T-cell leukemia.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449469.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA055035; United States / NCI NIH HHS / CA / CA55035; United States / NCI NIH HHS / CA / CA055035-14S1; United States / NCI NIH HHS / CA / CA055035-14; United States / NCI NIH HHS / CA / R01 CA055035-14S1; United States / NCI NIH HHS / CA / CA55035-S1; United States / NCI NIH HHS / CA / R01 CA055035-14
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CREB1 protein, human; 0 / Cyclic AMP Response Element-Binding Protein
  •  go-up   go-down


2. Pais-Correia AM, Sachse M, Guadagnini S, Robbiati V, Lasserre R, Gessain A, Gout O, Alcover A, Thoulouze MI: Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat Med; 2010 Jan;16(1):83-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses.
  • Human T cell leukemia virus type 1 (HTLV-1) is a lymphotropic retrovirus whose cell-to-cell transmission requires cell contacts.
  • HTLV-1-infected T lymphocytes form 'virological synapses', but the mechanism of HTLV-1 transmission remains poorly understood.
  • We show here that HTLV-1-infected T lymphocytes transiently store viral particles as carbohydrate-rich extracellular assemblies that are held together and attached to the cell surface by virally-induced extracellular matrix components, including collagen and agrin, and cellular linker proteins, such as tetherin and galectin-3.
  • Extracellular viral assemblies rapidly adhere to other cells upon cell contact, allowing virus spread and infection of target cells.
  • Their removal strongly reduces the ability of HTLV-1-producing cells to infect target cells.
  • Our findings unveil a novel virus transmission mechanism based on the generation of extracellular viral particle assemblies whose structure, composition and function resemble those of bacterial biofilms.
  • HTLV-1 biofilm-like structures represent a major route for virus transmission from cell to cell.
  • [MeSH-major] CD4-Positive T-Lymphocytes / virology. Extracellular Matrix / virology. HTLV-I Infections / transmission. Human T-lymphotropic virus 1 / physiology
  • [MeSH-minor] Biofilms. Concanavalin A. Gene Products, env / metabolism. Humans. Microscopy, Electron, Transmission. Virus Assembly / physiology. Virus Attachment. Virus Internalization

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Med. 2010 Jan;16(1):25-7 [20057417.001]
  • (PMID = 20023636.001).
  • [ISSN] 1546-170X
  • [Journal-full-title] Nature medicine
  • [ISO-abbreviation] Nat. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, env; 11028-71-0 / Concanavalin A
  •  go-up   go-down


3. Yu Q, Minoda Y, Yoshida R, Yoshida H, Iha H, Kobayashi T, Yoshimura A, Takaesu G: HTLV-1 Tax-mediated TAK1 activation involves TAB2 adapter protein. Biochem Biophys Res Commun; 2008 Jan 4;365(1):189-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HTLV-1 Tax-mediated TAK1 activation involves TAB2 adapter protein.
  • Human T cell leukemia virus type 1 (HTLV-1) Tax is an oncoprotein that plays a crucial role in the proliferation and transformation of HTLV-1-infected T lymphocytes.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Gene Products, tax / metabolism. Human T-lymphotropic virus 1 / metabolism. MAP Kinase Kinase Kinases / metabolism
  • [MeSH-minor] Binding Sites. Cell Line. Humans. NF-kappa B / metabolism. Ubiquitin-Protein Ligases / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986383.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Gene Products, tax; 0 / NF-kappa B; 0 / TAB2 protein, human; 0 / tax protein, Human T-lymphotrophic virus 1; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 2.7.11.25 / MAP kinase kinase kinase 7; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


Advertisement
4. Mori Y, Yoshimoto G, Kumano T, Miyamoto T, Iino T, Takenaka K, Iwasaki H, Harada N, Kinukawa N, Nagafuji K, Teshima T, Shimoda K, Akashi K, Harada M: Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation. Eur J Haematol; 2007 Jul;79(1):17-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.
  • OBJECTIVE: Patients with acute myelogenous leukaemia (AML) show co-existing frequently internal tandem duplications of FLT3 (FLT3-ITD) and mutations of nucleophosmin (NPM1-Mt).
  • We investigated the biological and clinical significance of FLT3-ITD and/or NPM1-Mt in this context.
  • By multivariate analysis, white blood cell count and peripheral blood blast cell count at diagnosis were significantly higher in patients with FLT3-ITD but not in those with only NPM1-Mt.
  • NPM1-Mt was significantly related to female gender, normal karyotype, and M4 or M5 disease according to French-American-British criteria.
  • CONCLUSION: FLT3-ITD may increase potential for cell proliferation to produce a leukaemic population; NPM1-Mt may cause cells to develop along the myelomonocytic lineage.
  • [MeSH-major] Antigens, CD34 / immunology. Biomarkers, Tumor / metabolism. Gene Duplication. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / immunology. Monocytes / metabolism. Mutation. Nuclear Proteins / genetics. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunophenotyping. Karyotyping. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598835.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


5. Chen YH, Huang XJ, Xu LP, Liu DH, Chen H, Zhang YC, Han W, Gao ZY, Wu T, Zhang XH, Lu DP: [A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors]. Zhonghua Nei Ke Za Zhi; 2006 Aug;45(8):624-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors].
  • OBJECTIVE: To compare the outcomes in hematological patients receiving unrelated peripheral blood stem cell transplants (UPBSCT) with those receiving unrelated bone marrow transplants (UBMT) in a retrospective analysis.
  • Graft versus host disease (GVHD) prophylaxis consisting of cyclosporine, methotrexate and mycophenolate mofetil were the same.
  • RESULTS: The two groups were matched for the following factors: gender, diagnosis, HLA-compatibility and conditioning regimens.
  • Eleven patients in the UPBSCT and 8 patients in the UBMT group were diagnosed with as chronic myeloid leukemia (CML); 9 and 12 as acute myelocytic leukemia (AML); 11 and 10 as acute lymphatic leukemia (ALL); 2 and 0 as severe aplastic anemia (SAA).
  • Although the cumulative incidence of grades II - IV acute GVHD and severe aGVHD in the UPBSCT group were less than in the UBMT group (33.04% vs 66.69%, 7.26% vs 34.52%, P < 0.05), there was no difference after the source of ATG was counted.
  • [MeSH-major] Bone Marrow Transplantation. Graft vs Host Disease / prevention & control. Leukemia / surgery. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Animals. Antibodies, Monoclonal / therapeutic use. Child. Female. Follow-Up Studies. Humans. Male. Rabbits. Retrospective Studies. Survival Rate. Swine. Transplantation Conditioning / methods


6. Weisser M, Haferlach C, Haferlach T, Schnittger S: Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML. Leuk Lymphoma; 2007 Nov;48(11):2145-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML.
  • For further insight in this rare entity the outcome of 65 inv(3)/t(3;3) positive AML cases were examined with special emphasis o n patient a nd disease related factors at diagnosis.
  • Advanced age and high initial WBC count were associated with shorter OS (p = 0.021 and p = 0.005, respectively).
  • Cases with monosomy 7 or the presence of FLT3-length mutations (FLT3-LM)--detected in 13% of cases--were not associated with an even more inferior outcome.
  • Allogeneic stem cell translplantation, performed in 12 cases, resulted in a probability of OS of 62% at 2 years.
  • (3) suggest that this group may benefit from allogeneic stem cell transplantation.
  • [MeSH-major] Aged. Chromosome Inversion. Chromosomes, Human, Pair 3. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Leukocyte Count. Translocation, Genetic
  • [MeSH-minor] Adult. Age Factors. Aged, 80 and over. Aminoglutethimide / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Cytarabine / therapeutic use. Danazol / therapeutic use. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Karyotyping. Male. Middle Aged. Mitoxantrone / therapeutic use. Prognosis. Survival Analysis. Tamoxifen / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. AMINOGLUTETHIMIDE .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Nov;48(11):2096-7 [17990175.001]
  • (PMID = 17926191.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 094ZI81Y45 / Tamoxifen; 0O54ZQ14I9 / Aminoglutethimide; BZ114NVM5P / Mitoxantrone; N29QWW3BUO / Danazol; MAC chemotherapy protocol; TAD protocol
  •  go-up   go-down


7. Ling JY, Sun XF, Yan SL, He LR, Zhen ZJ, Xia Y: [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. Ai Zheng; 2007 Apr;26(4):418-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Diagnosis of lymphocytic leukemia and non-Hodgkin's lymphoma (NHL) is based on bone marrow morphology.
  • Immunophenotyping will make diagnosis more precise through analyzing the origin and differentiation status of tumor, which is necessary for treatment and prognosis prediction.
  • This study was to analyze the immunophenotypic characteristics of lymphocytic leukemia and NHL with bone marrow involvement using flow cytometry (FCM).
  • METHODS: Bone marrow specimens from 112 patients with lymphocytic leukemia or NHL with bone marrow involvement were detected by FCM using antibodies of T, B and myeloid cell series.
  • RESULTS: In 45 cases of precursor B lymphoblastic leukemia/lymphoma (B-ALL/LBL), the antigens were mainly CD19, CD10, TdT, CD34, HLA-DR, and CD20.
  • In 32 cases of precursor T lymphoblastic leukemia/lymphoma (T-ALL/LBL), the antigens were mainly CD7, CD5, cytoplasmic (Cy)CD3, TdT, CD34, surface CD3 (sCD3), and HLA-DR.
  • Of the 77 cases of precursor ALL/LBL, 28(36.4%) expressed myeloid-associated antigens, such as CD13 and CD33; 9 (20.0%) cases of B-ALL/LBL coexpressed CD20 and CD34; 28(87.5%) cases of T-ALL/LBL coexpressed cyCD3 and TdT.
  • Among the 35 cases of mature B-cell malignancies, 17 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) mainly expressed CD19, CD20, CD5, HLA-DR, with coexpression of CD19 and CD5; 4 cases of diffuse large B-cell lymphoma (DLBCL) mainly expressed CD19, CD20, CD10, and HLA-DR; 3 cases of Burkitt's lymphoma (BL) mainly expressed CD19, CD10, CD20, and sIgM; 1 case of mantle cell lymphoma (MCL) expressed CD5, CD19, CD20, and HLA-DR.
  • Among the 10 mature T-cell malignancies, 5 cases of unspecialied peripheral T-cell lymphoma (PTCL) mainly expressed sCD3, CD5 and CD7, CD4 or CD8; 1 case of anaplastic large cell lymphoma (ALCL) expressed sCD3 and HLA-DR; 4 cases of NK/T-cell malignancies expressed CD56 and HLA-DR, CD4 or CD8 or CD7.
  • Mature lymphoid system malignancies didn't express early antigens, such as CD34 and TdT, but expressed myeloid-associated antigens, especially CD13 and CD33.
  • CONCLUSION: Multiparameter FCM can not only provide data of cell lineage and differentiation status but also detect phenotypic aberrancies, which is helpful for minimal residual disease detecting.
  • [MeSH-major] Antigens, CD / analysis. Bone Marrow / immunology. Immunophenotyping. Leukemia, Lymphoid / immunology. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Flow Cytometry. HLA-DR Antigens / analysis. Humans. Infant. Male. Middle Aged. Young Adult


8. Fey MF: [Salient clinical features of lymphoma and related lymphoproliferative disorders]. Ther Umsch; 2010 Oct;67(10):491-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Salient clinical features of lymphoma and related lymphoproliferative disorders].
  • The literature on malignant lymphomas has grown to an extent which is hardly palatable for general practitioners and non-lymphoma aficionados.
  • Nevertheless some lymphomas exhibit typical clinical and radiological features which permit to suspect the correct histopathological diagnosis even before a pathology report becomes available.
  • The present article points out such "case vignettes" of particular types of malignant lymphoma.
  • [MeSH-major] Lymphoma / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Burkitt Lymphoma / classification. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Diagnosis, Differential. Enteropathy-Associated T-Cell Lymphoma / classification. Enteropathy-Associated T-Cell Lymphoma / diagnosis. Enteropathy-Associated T-Cell Lymphoma / pathology. Female. Hodgkin Disease / classification. Hodgkin Disease / diagnosis. Hodgkin Disease / pathology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / classification. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / classification. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / pathology. Lymphoma, Mantle-Cell / classification. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Tomography, X-Ray Computed. Waldenstrom Macroglobulinemia / classification. Waldenstrom Macroglobulinemia / diagnosis. Waldenstrom Macroglobulinemia / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20886453.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


9. Ohsugi T, Kumasaka T, Okada S, Ishida T, Yamaguchi K, Horie R, Watanabe T, Umezawa K: Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines. Cancer Lett; 2007 Nov 18;257(2):206-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.
  • Adult T-cell leukemia (ATL) is an aggressive neoplasm caused by human T-cell leukemia virus type I (HTLV-I), which induces nuclear factor-kappaB (NF-kappaB), a molecule central to the ensuing neoplasia.
  • The NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) has been shown to inhibit NF-kappaB activation in Tax-expressing HTLV-I-infected cells.
  • In this study, we used NOD/SCID beta2-microglobulin(null) mice to show that intraperitoneal inoculation with Tax-deficient ATL cell lines caused rapid death, whereas DHMEQ-treated mice survived.
  • Furthermore, DHMEQ treatment after subcutaneous inoculation inhibited the growth of transplanted ATL cells.
  • These results demonstrate that DHMEQ has therapeutic efficacy on ATL cells, regardless of Tax expression.
  • [MeSH-major] Benzamides / pharmacology. Cyclohexanones / pharmacology. Gene Products, tax / deficiency. Leukemia, T-Cell / prevention & control. Xenograft Model Antitumor Assays / methods
  • [MeSH-minor] Adult. Animals. Apoptosis / drug effects. Cell Line, Tumor. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / metabolism. Humans. Mice. Mice, Inbred NOD. Mice, Knockout. Mice, SCID. NF-kappa B / antagonists & inhibitors. NF-kappa B / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Tumor Burden. beta 2-Microglobulin / genetics. beta 2-Microglobulin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17764832.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Benzamides; 0 / Cyclohexanones; 0 / Gene Products, tax; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / beta 2-Microglobulin; 0 / dehydroxymethylepoxyquinomicin
  •  go-up   go-down


10. Zimmermann U, Mentzel HJ, Wolf J, Fuchs D, Gruhn B, Zintl F, Kaiser WA: [MRI screening before stem cell transplantation--necessary?]. Rofo; 2008 Jan;180(1):30-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MRI screening before stem cell transplantation--necessary?].
  • PURPOSE: In the context of stem cell transplantation (SCT), we often observe neurological complications as a consequence of immune system suppression, conditioning therapy or prophylaxis and treatment of graft-versus-host disease.
  • The aim of this study was to evaluate the benefit of cerebral magnetic resonance imaging (MRI) prior to stem cell transplantation.
  • All MR images were obtained by a 1.5 T system.
  • RESULTS: In 5 of 116 children (4.3 %) we observed prior to SCT findings requiring immediate treatment although the patients did not show any clinical symptoms (1 x aspergilloma, 1 x hemorrhage of vascular anomaly).
  • CONCLUSION: The imaging findings requiring immediate treatment even though the children did not show any clinical signs, justify cerebral MR examinations prior to stem cell transplantation.
  • [MeSH-major] Bone Marrow Transplantation. Brain Diseases / diagnosis. Hematopoietic Stem Cell Transplantation. Leukemia / therapy. Magnetic Resonance Imaging. Neoplasms / therapy. Unnecessary Procedures
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Brain Neoplasms / diagnosis. Cerebral Ventricles / pathology. Child. Child, Preschool. Female. Hemangioma, Cavernous, Central Nervous System / diagnosis. Humans. Incidental Findings. Infant. Intracranial Arteriovenous Malformations / diagnosis. Male. Neuroaspergillosis / diagnosis. Opportunistic Infections / diagnosis. Paranasal Sinuses / pathology. Preoperative Care. Prospective Studies


11. Toulza F, Nosaka K, Tanaka Y, Schioppa T, Balkwill F, Taylor GP, Bangham CR: Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells. J Immunol; 2010 Jul 01;185(1):183-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells.
  • We recently reported that human T-lymphotropic virus type 1 (HTLV-1) infection is accompanied by a high frequency of CD4(+)FoxP3(+) cells in the circulation.
  • In asymptomatic carriers of HTLV-1 and in patients with HTLV-1-associated inflammatory and malignant diseases, a high FoxP3(+) cell frequency correlated with inefficient cytotoxic T cell-mediated killing of HTLV-1-infected cells.
  • In adult T cell leukemia/lymphoma (ATLL), the FoxP3(+) population was distinct from the leukemic T cell clones.
  • However, the cause of the increase in FoxP3(+) cell frequency in HTLV-1 infection was unknown.
  • In this study, we report that the plasma concentration of the chemokine CCL22 is abnormally high in HTLV-1-infected subjects and that the concentration is strongly correlated with the frequency of FoxP3(+) cells, which express the CCL22 receptor CCR4.
  • Further, we show that CCL22 is produced by cells that express the HTLV-1 transactivator protein Tax, and that the increased CCL22 enhances the migration and survival of FoxP3(+) cells in vitro.
  • Finally, we show that FoxP3(+) cells inhibit the proliferation of ex vivo, autologous leukemic clones from patients with ATLL.
  • We conclude that HTLV-1-induced CCL22 causes the high frequency of FoxP3(+) cells observed in HTLV-1 infection; these FoxP3(+) cells may both retard the progression of ATLL and HTLV-1-associated inflammatory diseases and contribute to the immune suppression seen in HTLV-1 infection, especially in ATLL.
  • [MeSH-major] Cell Proliferation. Chemokine CCL22 / physiology. Forkhead Transcription Factors / physiology. Human T-lymphotropic virus 1 / immunology. T-Lymphocytes, Regulatory / cytology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] CD4 Lymphocyte Count. Cell Survival / immunology. Cytotoxicity Tests, Immunologic. HTLV-I Infections / immunology. HTLV-I Infections / pathology. Humans. Jurkat Cells. Leukemia-Lymphoma, Adult T-Cell / immunology. Leukemia-Lymphoma, Adult T-Cell / pathology. T-Lymphocytes, Cytotoxic / cytology. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Cytotoxic / virology

  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Feb 15;95(4):1386-92 [10666215.001]
  • [Cites] Int J Cancer. 2009 Nov 15;125(10):2375-82 [19544530.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1505-11 [11861261.001]
  • [Cites] J Infect Dis. 2002 Oct 1;186(7):932-9 [12232833.001]
  • [Cites] Nat Rev Immunol. 2003 Mar;3(3):189-98 [12658267.001]
  • [Cites] J Neurovirol. 2003 Apr;9(2):228-35 [12707853.001]
  • [Cites] J Immunol. 2004 Oct 15;173(8):5121-9 [15470056.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(5):1653-7 [6951204.001]
  • [Cites] Lancet. 1986 May 3;1(8488):1031-2 [2871307.001]
  • [Cites] Cell. 1987 Apr 10;49(1):47-56 [3030566.001]
  • [Cites] Tohoku J Exp Med. 1989 Jan;157(1):1-11 [2711372.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] J Virol. 1994 Oct;68(10):6778-81 [8084014.001]
  • [Cites] J Biol Chem. 1998 Jan 16;273(3):1764-8 [9430724.001]
  • [Cites] J Virol Methods. 1998 Nov;75(1):21-6 [9820571.001]
  • [Cites] J Neurovirol. 1998 Dec;4(6):586-93 [10065900.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3848-53 [10097126.001]
  • [Cites] Nat Immunol. 2005 Apr;6(4):331-7 [15785758.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1037-44 [15809349.001]
  • [Cites] J Gen Virol. 2005 May;86(Pt 5):1515-23 [15831965.001]
  • [Cites] Clin Infect Dis. 2005 Jun 1;40(11):e90-6 [15889351.001]
  • [Cites] Cancer Sci. 2005 Aug;96(8):527-33 [16108835.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):295-307 [16557261.001]
  • [Cites] Blood. 2006 May 1;107(9):3639-46 [16403912.001]
  • [Cites] Immunity. 2006 Jul;25(1):129-41 [16860762.001]
  • [Cites] J Immunol. 2006 Oct 1;177(7):4488-94 [16982885.001]
  • [Cites] Cancer Sci. 2006 Nov;97(11):1139-46 [16952304.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2162-8 [17039235.001]
  • [Cites] J Immunol. 2008 Jan 15;180(2):931-9 [18178833.001]
  • [Cites] Immunology. 2008 Feb;123(2):157-63 [18067556.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2286-93 [18224687.001]
  • [Cites] Blood. 2008 May 15;111(10):5047-53 [18094326.001]
  • [Cites] J Immunol. 2008 Jun 1;180(11):7681-6 [18490771.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):607-10 [18645510.001]
  • [Cites] Eur J Haematol. 2008 Sep;81(3):209-17 [18510697.001]
  • [Cites] Cancer Immunol Immunother. 2009 Mar;58(3):441-7 [18685848.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):2000-9 [19244125.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2231-7 [19318474.001]
  • [Cites] J Immunol. 2009 May 1;182(9):5723-9 [19380819.001]
  • [Cites] PLoS Negl Trop Dis. 2009;3(6):e456 [19513105.001]
  • [Cites] Eur J Immunol. 2009 Jul;39(7):1700-12 [19582737.001]
  • [Cites] Blood. 2001 Aug 1;98(3):721-6 [11468172.001]
  • (PMID = 20525891.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 080871; United Kingdom / Medical Research Council / / G0501974; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL22 protein, human; 0 / Chemokine CCL22; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  • [Other-IDs] NLM/ EMS51736; NLM/ PMC3575032
  •  go-up   go-down


12. Saito M, Mori A, Irie T, Tanaka M, Morioka M, Uchiyama Y, Taukamoto E: [Picture in clinical hematology no. 41: PET/ CT findings in case of ATLL ]. Rinsho Ketsueki; 2009 Dec;50(12):1669-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Picture in clinical hematology no. 41: PET/ CT findings in case of ATLL ].
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / radiography. Leukemia-Lymphoma, Adult T-Cell / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20068272.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Shiratori S, Yasumoto A, Tanaka J, Shigematsu A, Yamamoto S, Nishio M, Hashino S, Morita R, Takahata M, Onozawa M, Kahata K, Kondo T, Ota S, Wakasa K, Sugita J, Koike T, Asaka M, Kasai M, Imamura M: A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect. Biol Blood Marrow Transplant; 2008 Jul;14(7):817-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect.
  • Adult T cell leukemia/lymphoma (ATL) is a highly aggressive T cell malignancy, and has a poor prognosis.
  • Recently, allogeneic-hematopoietic stem cell transplantation (allo-HSCT) has been suggested to improve the outcome.
  • We retrospectively analyzed 15 patients with ATL who had received allo-HSCT in 2 institutions in Hokkaido, Japan.
  • Calcineurin inhibitor dosage was reduced and administration was discontinued abruptly in 6 of the 15 patients for disease control; as a result, 4 (66.7%) of the 6 patients achieved complete response (CR) or partial response.
  • Therefore, a graft-versus-leukemia/lymphoma (GVL) effect might be induced by discontinuation of immunosuppression.
  • Thirteen of the 15 patients were followed up by monitoring HTLV-1 proviral DNA levels.
  • In 10 of the 11 patients with positive HTLV-1 proviral DNA before allo-HSCT, HTLV-1 proviral DNA became undetectable at least once after allo-HSCT, and only 1 of the 5 patients in whom HTLV-1 proviral DNA became detectable after allo-HSCT relapsed.
  • Compared to the results of past studies, these results show that allo-HSCT greatly improved the prognosis of ATL and suggest a contribution of the induction of a GVL effect.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation / methods. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. HTLV-I Infections / blood. HTLV-I Infections / therapy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Remission Induction. Retrospective Studies. Transplantation, Homologous. Viral Load

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Biol Blood Marrow Transplant. 2008 Sep;14(9):1079
  • (PMID = 18541202.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


14. Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A: Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer; 2005 Apr 15;103(8):1659-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
  • BACKGROUND: The advent of imatinib has considerably changed the treatment of chronic myeloid leukemia (CML).
  • Early studies demonstrated high rates of hematologic and cytogenetic responses in all phases of the disease after limited observation periods.
  • METHODS: The authors evaluated long-term outcome, rates of response, and resistance in 300 patients with BCR-ABL-positive leukemias (CML in chronic phase after failure to respond to interferon-alpha [CP], n = 139; accelerated phase [AP], n = 80; myeloid blast crisis [BC], n = 76; lymphoid BC and Philadelphia chromosome-positive acute lymphoblastic leukemia, n = 5) who entered clinical trials with imatinib in a single center after an observation time of 4.5 years.
  • In myeloid BC, the median survival period after the start of imatinib and after diagnosis of BC was 6 and 9 months, respectively.
  • Hematologic resistance occurred in 25%, 41%, and 92% of patients in CP, AP, and myeloid BC, respectively, and was associated with BCR-ABL mutations in 45% of patients and with clonal evolution in 58% of patients.
  • CONCLUSIONS: The data emphasized the need for a prolonged follow-up of patients treated with imatinib to define the clinical potential of the drug and to establish methods to optimize therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Fusion Proteins, bcr-abl / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Benzamides. Blast Crisis. Cytogenetic Analysis. Female. Humans. Imatinib Mesylate. Interferon-alpha / adverse effects. Male. Middle Aged. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Protein-Tyrosine Kinases / antagonists & inhibitors. Remission Induction. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15747376.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Interferon-alpha; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


15. Ferry JA, Fung CY, Zukerberg L, Lucarelli MJ, Hasserjian RP, Preffer FI, Harris NL: Lymphoma of the ocular adnexa: A study of 353 cases. Am J Surg Pathol; 2007 Feb;31(2):170-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma of the ocular adnexa: A study of 353 cases.
  • We studied the cases of 353 patients with lymphoma involving the ocular adnexa diagnosed at the Massachusetts General Hospital between 1974 and 2005.
  • In 277 cases, there was no known history of lymphoma.
  • Seventy-six patients had a history of lymphoma, with the ocular adnexa being involved at relapse or with progression of the previously diagnosed lymphoma.
  • The patients had marginal zone lymphoma (182 cases), follicular lymphoma (80 cases), mantle cell lymphoma (18 cases), small lymphocytic lymphoma/chronic lymphocytic leukemia (13 cases), lymphoplasmacytic lymphoma (4 cases), splenic marginal zone lymphoma (2 cases), low-grade B cell, not subclassified (19 cases), precursor B lymphoblastic lymphoma (3 cases), diffuse large B-cell lymphoma (26 cases), and 1 case each of high-grade B-cell lymphoma, not subclassified, peripheral T-cell lymphoma, unspecified type, extranodal NK/T-cell lymphoma, nasal type, and Hodgkin lymphoma, nodular sclerosis type.
  • Almost all marginal zone lymphoma patients (168 of 182, 92%) had primary ocular adnexal lymphoma.
  • Fourteen marginal zone lymphoma patients (8%) had a prior history of lymphoma, usually arising in another extranodal site.
  • Twenty-five of 80 (31%) follicular lymphoma patients had a prior history of lymphoma, usually arising in lymph nodes.
  • Patients with mantle cell lymphoma, chronic lymphocytic leukemia, lymphoplasmacytic lymphoma, and splenic marginal zone lymphoma almost always had a prior history of lymphoma or were known to have widespread disease at the time of diagnosis of ocular adnexal lymphoma.
  • A subset of the diffuse large B-cell lymphomas were associated with large destructive masses involving adjacent structures such as paranasal sinuses, raising the possibility that they may have arisen from one of the adjacent structures and involved the ocular adnexa by direct extension.
  • The relatively high proportion of low-grade lymphoma, not subclassified, highlights the difficulty that may arise in distinguishing different types of low-grade lymphoma, particularly when biopsies are small and artifactually distorted.
  • Ocular adnexal lymphoma is primarily a disease of older adults, with a slight female preponderance.
  • Most lymphomas are low-grade B-cell lymphomas, with marginal zone lymphoma being by far the most common type.
  • Marginal zone lymphoma typically involves the ocular adnexa primarily, whereas other types of low-grade B-cell lymphoma often involve the ocular adnexa secondarily.
  • High-grade B-cell lymphomas only occasionally involve the ocular adnexa, and T-cell lymphoma, NK-cell lymphoma, and Hodgkin lymphoma are only rarely encountered in this site.
  • [MeSH-major] Conjunctival Neoplasms / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology. Lymphoma / pathology. Orbital Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Female. Flow Cytometry. Humans. Immunoenzyme Techniques. Immunophenotyping. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Tears.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255761.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Uphoff CC, Denkmann SA, Steube KG, Drexler HG: Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines. J Biomed Biotechnol; 2010;2010:904767
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
  • The high prevalence of contaminated cell cultures suggests that viral contaminations might be distributed among cultures.
  • We investigated more than 460 primate cell lines for Epstein-Barr (EBV), hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus type 1 (HIV-1), human T-cell leukemia/lymphoma virus I and II (HTLV-I/-II), and squirrel monkey retrovirus (SMRV) infections for risk assessment.
  • None of the cell lines were infected with HCV, HIV-1, or HTLV-I/-II.
  • However, one cell line displayed reverse transcriptase activity.
  • Thirty-nine cell lines harbored EBV DNA sequences.
  • Studies on the lytic phase of EBV revealed that five cell lines produce EBV particles and six further cell lines produced EBV upon stimulation.
  • One cell line contained an integrated HBV genome fragment but showed no virus production.
  • Six cell lines were SMRV-infected.
  • Newly established cell lines should be tested for EBV infections to detect B-lymphoblastoid cell lines (B-LCL).
  • B-LCLs established with EBV from cell line B95-8 should be tested for SMRV infections.
  • [MeSH-major] Primates / virology. Viruses / genetics. Viruses / isolation & purification
  • [MeSH-minor] Animals. Blotting, Southern. Cell Line. DNA, Circular / analysis. HIV-1 / genetics. HIV-1 / isolation & purification. Hepacivirus / genetics. Hepacivirus / isolation & purification. Hepatitis B virus / genetics. Hepatitis B virus / isolation & purification. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / isolation & purification. Human T-lymphotropic virus 2 / genetics. Human T-lymphotropic virus 2 / isolation & purification. Humans. In Situ Hybridization, Fluorescence. Polymerase Chain Reaction. Retroviruses, Simian / genetics. Retroviruses, Simian / isolation & purification. Saimiri / virology. Viral Proteins / analysis

  • Genetic Alliance. consumer health - HIV.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 1992 Apr;4(3):205-10 [1382560.001]
  • [Cites] ALTEX. 2005;22(2):103-9 [15953965.001]
  • [Cites] J Virol Methods. 1992 Sep;39(3):259-68 [1430070.001]
  • [Cites] J Virol Methods. 1992 Dec 1;40(3):347-56 [1282132.001]
  • [Cites] Gastroenterology. 1993 Nov;105(5):1529-33 [8224658.001]
  • [Cites] Leukemia. 1994 Apr;8(4):652-8 [8152260.001]
  • [Cites] Leukemia. 1994 Aug;8(8):1385-91 [8057678.001]
  • [Cites] Leukemia. 1994 Sep;8(9):1510-26 [8090031.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] J Hepatol. 1998 Mar;28(3):396-403 [9551676.001]
  • [Cites] DNA Cell Biol. 1998 May;17(5):415-25 [9628585.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] Leukemia. 1998 Nov;12(11):1806-9 [9823957.001]
  • [Cites] Eur J Haematol. 1999 Jan;62(1):1-18 [9918306.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Oct 14;264(1):33-6 [10527836.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):967-8 [10580600.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(14):1878-85 [10711230.001]
  • [Cites] Leuk Res. 2002 Apr;26(4):329-33 [11839374.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2002 Feb;38(2):79-85 [11928999.001]
  • [Cites] J Virol. 2002 Jun;76(11):5612-26 [11991990.001]
  • [Cites] Haemophilia. 2002 May;8(3):236-43 [12010417.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):567-74 [15160920.001]
  • [Cites] Nature. 1973 Mar 2;242(5392):44-7 [4348458.001]
  • [Cites] Int J Cancer. 1974 Mar 15;13(3):363-76 [4362611.001]
  • [Cites] Neoplasma. 1974;21(6):619-27 [4141066.001]
  • [Cites] J Virol Methods. 2006 Sep;136(1-2):193-9 [16806502.001]
  • [Cites] Adv Cancer Res. 2007;97:81-109 [17419942.001]
  • [Cites] Beitr Pathol. 1975 May;155(1):72-8 [168861.001]
  • [Cites] Science. 1977 Jan 21;195(4275):289-92 [63993.001]
  • [Cites] Virology. 1980 Mar;101(2):553-7 [6244705.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] Int J Cancer. 1982 Jul 15;30(1):93-9 [6288581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Apr;80(7):1987-91 [6300885.001]
  • [Cites] J Virol. 1984 Apr;50(1):248-54 [6321792.001]
  • [Cites] Gene. 1984 Mar;27(3):279-88 [6329907.001]
  • [Cites] Cell Mol Biol. 1986;32(3):343-50 [3017561.001]
  • [Cites] Int J Cancer. 1987 Jan 15;39(1):89-93 [3098690.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Feb;84(4):1005-9 [3029758.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Mar;84(5):1332-6 [3029778.001]
  • [Cites] Eur J Biochem. 1987 Jun 1;165(2):393-401 [2439332.001]
  • [Cites] Blood. 1987 Nov;70(5):1665-72 [3478106.001]
  • [Cites] Clin Exp Immunol. 1988 Jul;73(1):23-8 [3262465.001]
  • [Cites] J Infect Dis. 1988 Dec;158(6):1193-7 [3198935.001]
  • [Cites] Virology. 1988 Dec;167(2):468-76 [3201749.001]
  • [Cites] J Exp Med. 1989 Jun 1;169(6):2191-8 [2543732.001]
  • [Cites] J Virol. 1990 Mar;64(3):1143-55 [2154599.001]
  • [Cites] Leuk Res. 1990;14(4):381-7 [2159091.001]
  • [Cites] J Med Virol. 1990 Apr;30(4):266-71 [2164560.001]
  • [Cites] Leukemia. 1991 Mar;5(3):221-4 [1849602.001]
  • [Cites] Leukemia. 1991 May;5(5):399-407 [1851909.001]
  • [Cites] Braz J Med Biol Res. 2004 Nov;37(11):1707-12 [15517087.001]
  • [Cites] Int J Cancer. 1992 Sep 30;52(3):451-4 [1339415.001]
  • (PMID = 20454443.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Circular; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2861168
  •  go-up   go-down


17. Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, Benoit Y, Biondi A, Cavé H, Dombret H, Fielding AK, Foà R, Gökbuget N, Goldstone AH, Goulden N, Henze G, Hoelzer D, Janka-Schaub GE, Macintyre EA, Pieters R, Rambaldi A, Ribera JM, Schmiegelow K, Spinelli O, Stary J, von Stackelberg A, Kneba M, Schrappe M, van Dongen JJ, European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL), International Berlin-Frankfurt-Münster Study Group (I-BFM-SG): Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia; 2010 Mar;24(3):521-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification.
  • For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR- and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.
  • The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials.
  • The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Flow Cytometry. Fusion Proteins, bcr-abl / genetics. Gene Rearrangement. Genes, Immunoglobulin. Humans. Neoplasm, Residual / diagnosis. Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033054.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 92
  •  go-up   go-down


18. Okudaira T, Hirashima M, Ishikawa C, Makishi S, Tomita M, Matsuda T, Kawakami H, Taira N, Ohshiro K, Masuda M, Takasu N, Mori N: A modified version of galectin-9 suppresses cell growth and induces apoptosis of human T-cell leukemia virus type I-infected T-cell lines. Int J Cancer; 2007 May 15;120(10):2251-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A modified version of galectin-9 suppresses cell growth and induces apoptosis of human T-cell leukemia virus type I-infected T-cell lines.
  • ATL is a fatal malignancy of T lymphocytes caused by HTLV-I infection and remains incurable.
  • Galectins are a family of animal lectins that function both extracellularly (by interacting with cell surface and extracellular matrix glycoproteins and glycolipids) and intracellularly (by interacting with cytoplasmic and nuclear proteins) to modulate signaling pathways.
  • We found that protease-resistant galectin-9 by modification of its linker peptide, hG9NC(null), prevented cell growth of HTLV-I-infected T-cell lines and primary ATL cells.
  • The suppression of cell growth was inhibited by lactose, but not by sucrose, indicating that beta-galactoside binding is essential for hG9NC(null)-induced cell growth suppression. hG9NC(null) induced cell cycle arrest by reducing the expression of cyclin D1, cyclin D2, cyclin B1, Cdk1, Cdk4, Cdk6, Cdc25C and c-Myc, and apoptosis by reducing the expression of XIAP, c-IAP2 and survivin.
  • Most of these genes are regulated by NF-kappaB, which plays a critical role in oncogenesis by HTLV-I. hG9NC(null) suppressed IkappaBalpha phosphorylation, resulting in suppression of NF-kappaB.
  • Most importantly, treatment with hG9NC(null) (6.7 mg/kg injected intraperitoneally every day) reduced tumor formation from an HTLV-I-infected T-cell line when these cells were inoculated subcutaneously into SCID mice.
  • Our results suggest that hG9NC(null) could be a suitable agent for the management of ATL.
  • [MeSH-major] Apoptosis / drug effects. Galectins / pharmacology. HTLV-I Infections / drug therapy. Human T-lymphotropic virus 1 / growth & development. Leukemia-Lymphoma, Adult T-Cell / therapy. T-Lymphocytes / pathology. T-Lymphocytes / virology
  • [MeSH-minor] Animals. Caspases / metabolism. Cell Cycle / drug effects. Cell Cycle / physiology. Cell Line, Tumor. Female. Galactosides / metabolism. Growth Inhibitors / pharmacology. Humans. Membrane Proteins. Mice. Mice, SCID. NF-kappa B / genetics. NF-kappa B / immunology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Virus / biosynthesis. beta-Galactosidase / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • [RetractionIn] Int J Cancer. 2011 Dec 1;129(11):2762-3 [21960263.001]
  • (PMID = 17278100.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Galactosides; 0 / Galectins; 0 / Growth Inhibitors; 0 / HAVCR2 protein, human; 0 / LGALS8 protein, human; 0 / LGALS9 protein, human; 0 / Membrane Proteins; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / Receptors, Virus; 0 / beta-galactoside; EC 3.2.1.23 / beta-Galactosidase; EC 3.4.22.- / Caspases
  •  go-up   go-down


19. Peloponese JM, Yeung ML, Jeang KT: Modulation of nuclear factor-kappaB by human T cell leukemia virus type 1 Tax protein: implications for oncogenesis and inflammation. Immunol Res; 2006;34(1):1-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of nuclear factor-kappaB by human T cell leukemia virus type 1 Tax protein: implications for oncogenesis and inflammation.
  • Human T cell leukemia virus type 1 (HTLV-1) is the causative agent of a fatal malignancy known as adult T cell leukemia (ATL) and an inflammatory disease named tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM).
  • HTLV-1 encodes an oncoprotein, Tax, which plays a significant role in the initiation of cellular transformation and the elicitation of the host's inflammatory responses.
  • [MeSH-major] Cell Transformation, Neoplastic / immunology. Gene Products, tax / immunology. HTLV-I Infections / immunology. Human T-lymphotropic virus 1 / immunology. Inflammation / immunology. NF-kappa B / immunology

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720895.001).
  • [ISSN] 0257-277X
  • [Journal-full-title] Immunologic research
  • [ISO-abbreviation] Immunol. Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / NF-kappa B
  • [Number-of-references] 102
  •  go-up   go-down


20. Sargent JT, Smith OP: Haematological emergencies managing hypercalcaemia in adults and children with haematological disorders. Br J Haematol; 2010 May;149(4):465-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypercalcaemia is a common metabolic complication of malignant disease often requiring emergency intervention.
  • Although it is more frequently associated with solid tumours, malignancy-associated hypercalcaemia (MAH) is seen in a significant number of patients with blood diseases.
  • Its association with myeloma and adult T-cell leukaemia/lymphoma is well recognized but the incidence of hypercalcaemia in other haematological neoplasms, affecting adults and children, is less clearly defined.
  • Haematologists need to be familiar with the clinical manifestations of, the differential diagnosis to be considered and the most effective management strategies that are currently available for MAH.
  • [MeSH-minor] Adult. Bone Density Conservation Agents / therapeutic use. Child. Diphosphonates / therapeutic use. Fluid Therapy / methods. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377591.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  • [Number-of-references] 96
  •  go-up   go-down


21. Marzano AV, Vezzoli P, Fanoni D, Venegoni L, Berti E: Primary cutaneous T-cell lymphoma expressing FOXP3: a case report supporting the existence of malignancies of regulatory T cells. J Am Acad Dermatol; 2009 Aug;61(2):348-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous T-cell lymphoma expressing FOXP3: a case report supporting the existence of malignancies of regulatory T cells.
  • Regulatory T (Treg) cells, which represent 5% to 10% of peripheral T cells, regulate the activities of T-cell subsets by performing immunosuppressive functions and thus preventing the development of autoimmune responses.
  • Recently, it has been demonstrated that the tumor cells in adult T-cell leukemia lymphomas can function as Treg, raising the question of whether any variant of primary cutaneous T-cell lymphoma may also express a regulatory phenotype.
  • We describe an extraordinary case of primary cutaneous T-cell lymphoma clinically characterized by protean cutaneous manifestations and histologically showing a pattern consistent with epidermotropic pleomorphic medium-/large-cell primary cutaneous T-cell lymphoma.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. Forkhead Transcription Factors / immunology. Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology. T-Lymphocytes, Regulatory / immunology


22. Miyano-Kurosaki N, Kira J, Barnor JS, Maeda N, Misawa N, Kawano Y, Tanaka Y, Yamamoto N, Koyanagi Y: Autonomous proliferation of HTLV-CD4+ T cell clones derived from human T cell leukemia virus type I (HTLV-I)-associated myelopathy patients. Microbiol Immunol; 2007;51(2):235-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autonomous proliferation of HTLV-CD4+ T cell clones derived from human T cell leukemia virus type I (HTLV-I)-associated myelopathy patients.
  • That HTLV-I infects CD4(+) T cells and enhances their cell growth has been shown as successful long-term in vitro proliferation in the presence of IL-2.
  • It is known that T cells isolated from HAM patients possess strong ability for cell proliferation in vitro and mRNA of various cytokines are abundantly expressed in CNS tissues of HAM patients.
  • In this study, we examined the relationship between cell proliferation and ability of in vitro cytokine production of CD4(+) T cell clones isolated from HAM patients.
  • We started a culture from a single cell to isolate cell clones immediately after drawing blood from the patients using limiting dilution method, which could allow the cell to avoid in vitro HTLV-I infection after initiation of culture.
  • Many cell clones were obtained and the rate of proliferation efficiency from a single cell was as high as 80%, especially in the 4 weeks' culture cells from HAM patients.
  • Our results indicate that the ability of cell proliferation in HAM patients is not restricted in HTLV-I-infected T cells.
  • HTLV-Iuninfected CD4(+) T cells, mainly Th0 cells, also have a strong ability to respond to IL-2-stimulation, showing that unusual immune activation on T cells has been observed in HAM patients.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / virology. Human T-lymphotropic virus 1 / immunology. Paraparesis, Tropical Spastic / immunology
  • [MeSH-minor] Adult. Aged. Clone Cells. Cytokines / genetics. Cytokines / immunology. DNA, Viral / chemistry. DNA, Viral / genetics. Female. Humans. Lymphocyte Activation. Male. Middle Aged. Polymerase Chain Reaction. Receptors, Antigen, T-Cell / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17310092.001).
  • [ISSN] 0385-5600
  • [Journal-full-title] Microbiology and immunology
  • [ISO-abbreviation] Microbiol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA, Viral; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


23. Tanaka Y, Nakasone H, Yamazaki R, Sato K, Sato M, Terasako K, Kimura S, Okuda S, Kako S, Oshima K, Tanihara A, Nishida J, Yoshikawa T, Nakatsura T, Sugiyama H, Kanda Y: Single-cell analysis of T-cell receptor repertoire of HTLV-1 Tax-specific cytotoxic T cells in allogeneic transplant recipients with adult T-cell leukemia/lymphoma. Cancer Res; 2010 Aug 1;70(15):6181-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-cell analysis of T-cell receptor repertoire of HTLV-1 Tax-specific cytotoxic T cells in allogeneic transplant recipients with adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia (ATL) is a lymphoproliferative malignancy associated with human T-cell lymphotropic virus type 1 (HTLV-1) infection.
  • Recently, it has been shown that allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for ATL, and that HTLV-1 Tax-specific CD8(+) cytotoxic T cells (CTL) contribute to the graft-versus-ATL effect.
  • In the present study, we, for the first time, analyzed the T-cell receptor (TCR) repertoire of isolated Tax(301-309) (SFHSLHLLF)-specific CTLs in HLA-A*2402(+) ATL patients before and after allo-HSCT by single-cell reverse transcription-PCR.
  • In addition, a unique conserved amino acid motif of "P-D/P-R" in TCR-beta complementarity-determining region 3 in either BV7- or BV18-expressing CTLs was observed not only in all of the samples from ATL patients, but also in samples from the same patient before and after HSCT.
  • Furthermore, the P-D/P-R motif-bearing CTL clones established from peripheral blood samples after HSCT exhibited strong killing activity against the HTLV-1-infected T cells of the patient.
  • Hence, Tax(301-309)-specific CTLs in ATL patients might have a preference for TCR construction and induce strong immune responses against the HTLV-1-infected T cells of patients, which contribute to the graft-versus-ATL effects after allo-HSCT.
  • [MeSH-major] Gene Products, tax / immunology. Hematopoietic Stem Cell Transplantation. Human T-lymphotropic virus 1 / immunology. Leukemia-Lymphoma, Adult T-Cell / immunology. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Amino Acid Motifs. HLA-A Antigens / immunology. HLA-A24 Antigen. Humans. Peptide Fragments / immunology. Receptors, Antigen, T-Cell / immunology. Receptors, Antigen, T-Cell, alpha-beta / immunology

  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647322.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / HLA-A Antigens; 0 / HLA-A*24:02 antigen; 0 / HLA-A24 Antigen; 0 / Peptide Fragments; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / tax protein, Human T-lymphotrophic virus 1
  •  go-up   go-down


24. Erben P, Gosenca D, Müller MC, Reinhard J, Score J, Del Valle F, Walz C, Mix J, Metzgeroth G, Ernst T, Haferlach C, Cross NC, Hochhaus A, Reiter A: Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica; 2010 May;95(5):738-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Rapid identification of diverse fusion genes with involvement of PDGFRA or PDGFRB in eosinophilia-associated myeloproliferative neoplasms is essential for adequate clinical management but is complicated by the multitude and heterogeneity of partner genes and breakpoints.
  • RESULTS: At diagnosis, all patients with known fusion genes involving PDGFRA (n=5; 51 patients) or PDGFRB (n=5; 7 patients) showed significantly increased normalized expression levels compared to 191 patients with fusion gene-negative eosinophilia or healthy individuals (PDGFRA/ABL: 0.73 versus 0.0066 versus 0.0064, P<0.0001; PDGFRB/ABL: 196 versus 3.8 versus 5.85, P<0.0001).
  • Furthermore, significant overexpression of PDGFRB was found in a patient with an eosinophilia-associated myeloproliferative neoplasm with uninformative cytogenetics and an excellent response to imatinib.
  • CONCLUSIONS: Quantitative reverse transcriptase polymerase chain reaction analysis is a simple and useful adjunct to standard diagnostic assays to detect clinically significant overexpression of PDGFRA and PDGFRB in eosinophilia-associated myeloproliferative neoplasms or related disorders.
  • [MeSH-major] Genetic Testing / methods. Oncogene Proteins, Fusion / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. Receptor, Platelet-Derived Growth Factor beta / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amino Acid Sequence. Base Sequence. Cells, Cultured. Child. Child, Preschool. Eosinophilia / diagnosis. Eosinophilia / genetics. Female. HL-60 Cells. Humans. Male. Middle Aged. Molecular Sequence Data. Myeloproliferative Disorders / diagnosis. Myeloproliferative Disorders / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1994 Jan;8(1):186-9 [8289486.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7392-401 [15314151.001]
  • [Cites] DNA Res. 1995 Aug 31;2(4):167-74, 199-210 [8590280.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):192-202 [10502316.001]
  • [Cites] Leukemia. 2006 May;20(5):827-32 [16498388.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1175-8 [16572202.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Oct;45(10):950-6 [16845659.001]
  • [Cites] Int J Oncol. 2006 Dec;29(6):1555-60 [17088996.001]
  • [Cites] Blood. 2007 Jan 1;109(1):61-4 [16960151.001]
  • [Cites] Haematologica. 2007 Feb;92(2):163-9 [17296564.001]
  • [Cites] Curr Drug Targets. 2007 Feb;8(2):205-16 [17305499.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1183-8 [17377585.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4635-40 [17299092.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):77-81 [17555450.001]
  • [Cites] Haematologica. 2007 Sep;92(9):1173-9 [17666373.001]
  • [Cites] Leukemia. 2008 Jan;22(1):14-22 [17882280.001]
  • [Cites] Leukemia. 2008 Jan;22(1):96-102 [17943168.001]
  • [Cites] Genes Chromosomes Cancer. 2008 May;47(5):379-85 [18205209.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1320-34 [18528425.001]
  • [Cites] Br J Haematol. 2008 Dec;143(5):707-15 [18950453.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Feb;48(2):179-83 [19006078.001]
  • [Cites] Leukemia. 2009 Feb;23(2):332-9 [18987650.001]
  • [Cites] Leukemia. 2009 Feb;23(2):271-8 [18987651.001]
  • [Cites] J Cell Mol Med. 2009 Feb;13(2):215-37 [19175693.001]
  • [Cites] Hum Pathol. 2003 Aug;34(8):809-13 [14506644.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3592-8 [10910073.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):915-9 [11286471.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3910-8 [11389034.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1776-84 [11861295.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1636-41 [11920522.001]
  • [Cites] Hum Mol Genet. 2002 Jun 1;11(12):1391-7 [12023981.001]
  • [Cites] EMBO J. 2002 Jun 3;21(11):2724-35 [12032085.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):481-7 [12181402.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38627-34 [12181311.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1013-34 [12764363.001]
  • [Cites] Cell. 1994 Apr 22;77(2):307-16 [8168137.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2392-400 [14523462.001]
  • [Cites] Blood. 2004 Jul 15;104(2):535-42 [15054045.001]
  • [CommentIn] Haematologica. 2010 May;95(5):696-8 [20442440.001]
  • (PMID = 20107158.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Other-IDs] NLM/ PMC2864379
  •  go-up   go-down


25. Woodard P, Barfield R, Hale G, Horwitz E, Leung W, Ribeiro R, Rubnitz J, Srivistava DK, Tong X, Yusuf U, Raimondi S, Pui CH, Handgretinger R, Cunningham JM: Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatr Blood Cancer; 2006 Dec;47(7):931-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome.
  • BACKGROUND: Therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) carry a poor prognosis.
  • PROCEDURE: The effects of demographic, donor, and disease-related factors were analyzed to determine their effects on overall and disease-free survival (OS, DFS), relapse, and non-relapse mortality (NRM).
  • The 1-year cumulative risk of grade III-IV acute graft-versus-host disease (GVHD) and relapse were 23.7 +/- 7.0% and 18.7 +/- 6.5%, respectively.
  • The percentage of pre-transplant bone marrow (BM) blasts was positively associated with relapse (P = 0.05), while the percentage of BM blasts at diagnosis of therapy-related disease tended to associate with NRM (P = 0.07).
  • NRM was higher among patients who did not develop acute GVHD as compared to those with grade 1-2 acute GVHD (69.2 +/- 14.2% vs. +/- 12.7%, respectively), while NRM was 100% in patients with grade III-IV acute GVHD (P = 0.007).
  • CONCLUSIONS: The percentage of BM blasts is associated with relapse in these disorders.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy. Neoplasms, Second Primary / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Graft vs Host Disease / etiology. Humans. Treatment Outcome


26. Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, Bethencourt C, Parody R, Deben G, Bello JL, Feliu E, Programa para el Estudio y Tratamiento de Hemopatias Malignas Group: Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer; 2006 Jun 15;106(12):2540-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
  • Recurrence of acute lymphoblastic leukemia (ALL) in the central nervous system (CNS) confers a poor prognosis, although to the authors' knowledge, only a few studies have analyzed this issue in adults.
  • For the current study, the authors analyzed the frequency, predictive factors, and prognosis of CNS involvement and recurrence in adult patients with ALL who did not receive cranial irradiation for CNS prophylaxis.
  • Four hundred sixty-seven adult patients (age > or = 15 years) with ALL were treated on 4 protocols: ALL-89 (standard-risk and high-risk ALL; n = 108 patients), ALL-93 (high-risk ALL; n = 222 patients), ALL-96 (standard-risk ALL; n = 84 patients), and ALL3-97 (Burkitt leukemia; n = 53 patients).
  • CNS involvement at diagnosis was observed in 18 patients (3.9%).
  • A lactate dehydrogenase level > 1000 U/L was the only factor associated with the risk of CNS recurrence.
  • The only 2 survivors underwent stem cell transplantation.
  • The frequency of CNS recurrence in adult patients with ALL who do not receive radiotherapy for CNS prophylaxis was similar to the frequency observed in protocols that included cranial irradiation.
  • A lactate dehydrogenase value >1000 U/L was the only factor found to be associated with CNS recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Incidence. Lactate Dehydrogenases / analysis. Male. Methotrexate / administration & dosage. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16700036.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 1.1.- / Lactate Dehydrogenases; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


27. Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Huan C, Wei H, Yu-Hong C, Jing-Zhi W, Yao C, Xiao-Hui Z, Hong-Xia S, Dao-Pei L: HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med; 2008;40(6):444-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
  • BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only proven curative therapy for chronic myeloid leukemia (CML), but lack of human leukocyte antigen (HLA)-matched sibling or unrelated donors has restricted its application.
  • RESULTS: Our data showed that the cumulative incidence of acute graft-versus-host disease (GVHD) was 64.52%, and grade III-IV was 26.45%, 61.79% had chronic GVHD, and 28.93% had extensive chronic GVHD.
  • Probability of 1-year and 4-year leukemia-free survival was similar in chronic phase (CP) 1, CP2/CR2, accelerated phase, and blast crisis patients.
  • Multivariate analysis indicated that factors affecting transplantation outcomes were HLA-B+DR mismatches versus others for II-III acute GVHD and III-IV acute GVHD, the stage of disease at transplantation for relapse, and the time from diagnosis to transplantation for leukemia-free survival, overall survival, and transplantation-related mortality.
  • [MeSH-major] Blast Crisis / therapy. Hematopoietic Stem Cell Transplantation / methods. Histocompatibility Testing. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Directed Tissue Donation. Female. Graft Survival. Graft vs Host Disease. Humans. Male. Middle Aged. Opportunistic Infections. Survival Analysis. Transplantation Conditioning. Transplantation, Homologous. Young Adult


28. Kobayashi H, Ngato T, Sato K, Aoki N, Kimura S, Tanaka Y, Aizawa H, Tateno M, Celis E: In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes. Clin Cancer Res; 2006 Jun 15;12(12):3814-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes.
  • PURPOSE: Adult T-cell leukemia/lymphoma induced by human T-cell leukemia virus type 1 (HTLV-1) is usually a fatal lymphoproliferative malignant disease.
  • HTLV-1 Tax protein plays a critical role in HTLV-1-associated leukemogenesis and is an attractive target for vaccine development.
  • Although HTLV-1 Tax is the most dominant antigen for HTLV-1-specific CD8(+) CTLs in HTLV-1-infected individuals, few epitopes recognized by CD4(+) helper T lymphocytes in HTLV-1 Tax protein have been described.
  • The aim of the present study was to study T-helper-cell responses to HTLV-1 Tax and to identify naturally processed MHC class II-restricted epitopes that could be used for vaccine development.
  • EXPERIMENTAL DESIGN: An MHC class II binding peptide algorithm was used to predict potential T-helper cell epitope peptides from HTLV-1 Tax.
  • We assessed the ability of the corresponding peptides to elicit helper T-cell responses by in vitro vaccination of purified CD4(+) T lymphocytes.
  • RESULTS: Peptides Tax(191-205) and Tax(305-319) were effective in inducing T-helper-cell responses.
  • Both these epitopes were found to be naturally processed by HTLV-1(+) T-cell lymphoma cells and by autologous antigen-presenting cells that were pulsed with HTLV-1 Tax(+) tumor lysates.
  • Notably, the two newly identified helper T-cell epitopes are found to lie proximal to known CTL epitopes, which will facilitate the development of prophylactic peptide-based vaccine capable of inducing simultaneous CTL and T-helper responses.
  • CONCLUSION: Our data suggest that HTLV-1 Tax protein could serve as tumor-associated antigen for CD4(+) helper T cells and that the present epitopes might be used for T-cell-based immunotherapy against tumors expressing HTLV-1.

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Mar 15;85(6):1547-54 [7534136.001]
  • [Cites] J Virol. 1994 May;68(5):2860-8 [7512153.001]
  • [Cites] Clin Diagn Lab Immunol. 1994 Mar;1(2):176-81 [7496941.001]
  • [Cites] Annu Rev Immunol. 1997;15:15-37 [9143680.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3363-73 [9531296.001]
  • [Cites] J Exp Med. 1999 Jan 18;189(2):371-80 [9892619.001]
  • [Cites] J Virol. 1999 Jul;73(7):6031-40 [10364355.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):257-67 [15551352.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3869-78 [15897588.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jul;55(7):850-60 [16220325.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):399-412 [7527817.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1386-92 [10666215.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):567-72 [10662802.001]
  • [Cites] J Virol. 2000 Oct;74(20):9610-6 [11000233.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5228-36 [11016652.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4773-8 [11406551.001]
  • [Cites] Int J Exp Pathol. 2001 Jun;82(3):135-47 [11488989.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7577-84 [11606397.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1775-83 [11734593.001]
  • [Cites] Blood. 2002 Jan 1;99(1):88-94 [11756157.001]
  • [Cites] Blood. 2002 May 1;99(9):3335-41 [11964301.001]
  • [Cites] J Immunol. 2002 Aug 15;169(4):2172-9 [12165547.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3219-25 [12374692.001]
  • [Cites] Vaccine. 2003 Jun 20;21(21-22):2767-81 [12798617.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5386-93 [14614024.001]
  • [Cites] Leukemia. 2004 Jan;18(1):126-32 [14574331.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):391-9 [14729650.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1735-43 [14734756.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Jun;4(3):369-76 [15161436.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):7053-62 [15501985.001]
  • [Cites] Leukemia. 1994 Apr;8 Suppl 1:S54-9 [8152305.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] Science. 1984 Apr 20;224(4646):297-9 [6231724.001]
  • [Cites] J Immunol. 1984 Aug;133(2):1037-41 [6203964.001]
  • [Cites] Ann Neurol. 1988;23 Suppl:S143-50 [2894806.001]
  • [Cites] Nature. 1990 Nov 15;348(6298):245-8 [2146511.001]
  • [Cites] J Clin Invest. 1991 Mar;87(3):761-6 [1999493.001]
  • [Cites] Int J Cancer. 1991 Jun 19;48(4):623-30 [1710610.001]
  • [Cites] Int Immunol. 1991 Aug;3(8):761-7 [1911545.001]
  • [Cites] J Virol. 1992 May;66(5):2928-33 [1373197.001]
  • [Cites] Virology. 1992 Jun;188(2):628-36 [1374983.001]
  • [Cites] J Virol. 1992 Oct;66(10):5879-89 [1326649.001]
  • [Cites] J Exp Med. 1993 Jun 1;177(6):1567-73 [8496677.001]
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):582-8 [8514449.001]
  • [Cites] J Immunol. 1993 Jul 15;151(2):1013-24 [7687611.001]
  • [Cites] J Virol. 1995 Oct;69(10):6077-89 [7545241.001]
  • (PMID = 16778109.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA103921; United States / NCI NIH HHS / CA / R01CA80782; United States / NCI NIH HHS / CA / R01CA103921; United States / NCI NIH HHS / CA / R01 CA080782; United States / NCI NIH HHS / CA / P50CA91956; United States / NCI NIH HHS / CA / P50 CA091956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / HLA-D Antigens; 0 / Peptides
  • [Other-IDs] NLM/ NIHMS14245; NLM/ PMC1986724
  •  go-up   go-down


29. Tözsér J, Weber IT: The protease of human T-cell leukemia virus type-1 is a potential therapeutic target. Curr Pharm Des; 2007;13(12):1285-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The protease of human T-cell leukemia virus type-1 is a potential therapeutic target.
  • Human T-cell leukemia virus type-1 (HTLV-1) is associated with a number of human diseases.
  • Although the mechanism by which the virus causes diseases is still not known, studies indicate that viral replication is critical for the development of HTLV-1 associated myelopathy, and initial studies suggested that blocking replication with reverse transcriptase inhibitors had a therapeutic effect.
  • Therefore, based on the success of HIV-1 protease inhibitors, the HTLV-1 protease is also a potential target for chemotherapy.
  • Furthermore, mutated residues in HIV-1 protease that confer drug resistance are frequently seen in equivalent positions of other retroviral proteases, like HTLV-1 protease.
  • Therefore, comparison of HTLV-1 and HIV-1 proteases is expected to aid the rational design of broad spectrum inhibitors effective against various retroviral proteases, including the mutant HIV-1 enzymes appearing in drug resistance.
  • This review describes the characteristics of HTLV-1 protease, makes comparison with HIV-1 protease, and discusses the status of inhibitor development for the HTLV-1 protease.

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504236.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM062920; United States / NIGMS NIH HHS / GM / GM 062920; United States / FIC NIH HHS / TW / TW01001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protease Inhibitors; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / HTLV-1 protease
  • [Number-of-references] 45
  •  go-up   go-down


30. Fritsch-Stork RD, Leguit RJ, Derksen RH: Rapidly fatal HTLV-1-associated T-cell leukemia/lymphoma in a patient with SLE. Nat Rev Rheumatol; 2009 May;5(5):283-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly fatal HTLV-1-associated T-cell leukemia/lymphoma in a patient with SLE.
  • INVESTIGATIONS: Physical and neurological examination and laboratory analyses, including biochemical, hematological and electrophoresis tests, X-ray of the lumbar spine, pelvis and chest, mammography, MRI of the lumbar spine, thoracic and abdominal CT, and biopsy of a peripheral lymph node and bone marrow with immunohistochemistry and serology for human T-cell lymphotrophic virus (HTLV) 1 and 2.
  • DIAGNOSIS: HTLV-1-associated acute adult T-cell leukemia/lymphoma with bone marrow infiltration and hypercalcemia.
  • Reaching the correct diagnosis was difficult and only possible through close collaboration with the pathologist and with consideration of the patient's ethnic and geographical background.
  • The patient developed tumor lysis syndrome and died 3 weeks after the diagnosis was made.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / complications. Lupus Erythematosus, Systemic / complications
  • [MeSH-minor] Azathioprine / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Drug Therapy, Combination. Fatal Outcome. Female. Glucocorticoids / therapeutic use. HTLV-I Antibodies / blood. Human T-lymphotropic virus 1 / immunology. Human T-lymphotropic virus 1 / isolation & purification. Humans. Immunocompromised Host. Immunosuppressive Agents / therapeutic use. Middle Aged. Prednisone / therapeutic use

  • MedlinePlus Health Information. consumer health - Lupus.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19412195.001).
  • [ISSN] 1759-4804
  • [Journal-full-title] Nature reviews. Rheumatology
  • [ISO-abbreviation] Nat Rev Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / HTLV-I Antibodies; 0 / Immunosuppressive Agents; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; MRK240IY2L / Azathioprine; VB0R961HZT / Prednisone
  •  go-up   go-down


31. Aiello A, Fattorusso E, Luciano P, Menna M, Calzado MA, Muñoz E, Bonadies F, Guiso M, Sanasi MF, Cocco G, Nicoletti R: Synthesis of structurally simplified analogues of aplidinone A, a pro-apoptotic marine thiazinoquinone. Bioorg Med Chem; 2010 Jan 15;18(2):719-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study evidenced one of the synthetic analogues (11) as a potent cytotoxic and pro-apoptotic agent against several tumor cell lines which also inhibits the TNFalpha-induced NF-kappaB activation in a human leukemia T cell line.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Computer Simulation. Drug Screening Assays, Antitumor. Humans. Molecular Structure. NF-kappa B / metabolism. Structure-Activity Relationship. Tumor Necrosis Factor-alpha / antagonists & inhibitors. Tumor Necrosis Factor-alpha / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20031419.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-kappa B; 0 / Quinones; 0 / Tumor Necrosis Factor-alpha; 0 / aplidinone A
  •  go-up   go-down


32. Gómez-Acevedo H, Li MY: Backward bifurcation in a model for HTLV-I infection of CD4+ T cells. Bull Math Biol; 2005 Jan;67(1):101-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Backward bifurcation in a model for HTLV-I infection of CD4+ T cells.
  • Human T-cell Lymphotropic Virus Type I (HTLV-I) primarily infects CD4+ helper T cells.
  • HTLV-I infection is clinically linked to the development of Adult T-cell Leukemia/Lymphoma and of HTLV-I Associated Myelopathy/Tropical Spastic Paraparesis, among other illnesses.
  • HTLV-I transmission can be either horizontal through cell-to-cell contact, or vertical through mitotic division of infected CD4+ T cells.
  • It has been observed that HTLV-I infection has a high proviral load but a low rate of proviral genetic variation.
  • We consider and analyze a mathematical model for HTLV-I infection of CD4+ T cells that incorporates both horizontal and vertical transmission.
  • [MeSH-major] CD4-Positive T-Lymphocytes / virology. Computer Simulation. Human T-lymphotropic virus 1 / growth & development. Models, Biological
  • [MeSH-minor] Algorithms. Cell Death. Cell Proliferation. Humans

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691541.001).
  • [ISSN] 0092-8240
  • [Journal-full-title] Bulletin of mathematical biology
  • [ISO-abbreviation] Bull. Math. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


33. Mahieux R, Gessain A: Adult T-cell leukemia/lymphoma and HTLV-1. Curr Hematol Malig Rep; 2007 Oct;2(4):257-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma and HTLV-1.
  • Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) was the first oncogenic human retrovirus to be discovered, more than 25 years ago.
  • HTLV-1 infects 15 to 20 million individuals worldwide.
  • HTLV-1 causes two major diseases: adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM).
  • ATLL can be classified into four major subtypes: a smoldering type, a chronic type, a lymphoma type, and a leukemic type.
  • Because of intrinsic chemoresistance and severe immunosuppression, the survival rate of ATLL patients, especially those who develop the acute leukemic or lymphoma forms, is very poor, and such clonal malignant CD4 expansion remains one of the most severe lymphoproliferations.
  • [MeSH-major] Human T-lymphotropic virus 1 / pathogenicity. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arsenicals / therapeutic use. CD4-Positive T-Lymphocytes / virology. Clinical Trials as Topic. Drug Resistance, Neoplasm. Endemic Diseases. Female. Gene Products, tax / physiology. Genes, pX. Humans. Immunoglobulin G / therapeutic use. Immunophenotyping. Immunotherapy. Infant, Newborn. Infectious Disease Transmission, Vertical. Interferon-alpha / therapeutic use. Male. Oxides / therapeutic use. Paraparesis, Tropical Spastic / epidemiology. Paraparesis, Tropical Spastic / virology. Pregnancy. Pregnancy Complications, Infectious. Zidovudine / therapeutic use

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S20-5 [8797699.001]
  • [Cites] Int J Cancer. 1999 Oct 29;83(3):291-8 [10495418.001]
  • [Cites] Br J Haematol. 1998 Dec;103(3):721-8 [9858223.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Apr;81(8):2534-7 [6326131.001]
  • [Cites] Blood. 1992 Jan 15;79(2):477-80 [1730092.001]
  • [Cites] Blood. 1991 Feb 15;77(4):896-905 [1993227.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1553-9 [16236609.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):419-30 [15543232.001]
  • [Cites] Cancer Sci. 2005 May;96(5):249-55 [15904464.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Immunity. 2000 Nov;13(5):657-64 [11114378.001]
  • [Cites] Retrovirology. 2007 Apr 14;4:27 [17433108.001]
  • [Cites] Int J Cancer. 1995 Mar 16;60(6):773-6 [7896443.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):2052-7 [17278106.001]
  • [Cites] Blood. 2005 May 15;105(10):4143-5 [15665110.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):720-5 [16407133.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1386-92 [10666215.001]
  • [Cites] Cancer. 1995 Apr 1;75(7):1598-607 [8826916.001]
  • [Cites] Clin Lab Haematol. 2005 Aug;27(4):235-41 [16048490.001]
  • [Cites] Blood. 2006 Dec 15;108(13):3979-82 [16917009.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3060-8 [17138822.001]
  • [Cites] Blood. 1999 Jan 1;93(1):278-83 [9864171.001]
  • [Cites] Blood. 2006 May 15;107(10 ):3976-82 [16424388.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1838-45 [14592824.001]
  • [Cites] Blood. 1983 Oct;62(4):758-66 [6224522.001]
  • [Cites] Oncogene. 2000 Oct 12;19(43):4954-60 [11042682.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):491-3 [7960218.001]
  • [Cites] Blood. 2001 Dec 15;98 (13):3762-9 [11739184.001]
  • [Cites] Hematol Oncol. 1986 Jan-Mar;4(1):59-65 [3009298.001]
  • [Cites] J Clin Immunol. 2007 Jan;27(1):1-18 [17216565.001]
  • [Cites] J Virol. 2002 Dec;76(24):12813-22 [12438606.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2462-71 [15956280.001]
  • [Cites] J Virol. 1995 May;69(5):2863-8 [7707509.001]
  • [Cites] Int J Cancer. 1988 Apr 15;41(4):505-12 [2895748.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1828-34 [12176906.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2849-55 [11023521.001]
  • [Cites] Int Immunol. 2006 Feb;18(2):269-77 [16361311.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):336-61 [15129647.001]
  • [Cites] Lancet Infect Dis. 2007 Apr;7(4):266-81 [17376384.001]
  • [Cites] Cancer. 1985 Feb 1;55(3):615-9 [2981152.001]
  • [Cites] Int J Cancer. 1989 Feb 15;43(2):250-3 [2917802.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):743-51 [10354140.001]
  • [Cites] Int J Cancer. 1999 Sep 9;82(6):832-6 [10446450.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Hematol J. 2004;5(2):130-4 [15048063.001]
  • [Cites] J Infect Dis. 2005 May 1;191(9):1490-7 [15809908.001]
  • [Cites] Leukemia. 2005 May;19(5):829-34 [15744352.001]
  • (PMID = 20425378.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Gene Products, tax; 0 / Immunoglobulin G; 0 / Interferon-alpha; 0 / Oxides; 0 / tax protein, Human T-lymphotrophic virus 1; 3A189DH42V / alemtuzumab; 4B9XT59T7S / Zidovudine; CUJ2MVI71Y / daclizumab; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 63
  •  go-up   go-down


34. Yoshie O: Expression of CCR4 in adult T-cell leukemia. Leuk Lymphoma; 2005 Feb;46(2):185-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CCR4 in adult T-cell leukemia.
  • Adult T-cell leukemia (ATL) is a malignancy of mature T cells that is etiologically associated with human T-cell leukemia virus type 1 (HTLV-1).
  • The frequent manifestation of ATL is infiltration of leukemic cells into various organs.
  • Besides certain cell adhesion molecules and matrix metalloproteineses, chemokine receptors may play important roles in tissue infiltration of ATL.
  • Identification of a unique set of chemokine receptors expressed by ATL would thus provide valuable information about the molecular mechanism of tissue infiltration of ATL.
  • This may also reveal that ATL frequently develops from a certain subset of T cells that express a particular set of chemokine receptors.
  • Since HTLV-1 encodes a potent viral transcriptional activator Tax, which is known to induce various cellular genes, expression of some chemokine receptors may be affected by Tax.
  • This, however, may relate more to HTLV-1-infected T cells, since ATL cells usually do not express Tax.
  • Finally, identification of a unique set of chemokine receptors expressed by ATL may also provide a new therapeutic target.
  • These considerations prompted us to examine the chemokine receptor expression in ATL.
  • We found that in the majority of ATL cases, leukemic cells consistently express CCR4.
  • Since CCR4 is known to be involved in T cell migration into skin, this may in part explain the frequent skin infiltration in ATL.
  • Thus, the majority of ATL may predominantly originate from either Th2 or regulatory T cells.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / immunology. Receptors, Chemokine / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621800.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCR4 protein, human; 0 / Receptors, CCR4; 0 / Receptors, Chemokine
  • [Number-of-references] 44
  •  go-up   go-down


35. Hieshima K, Nagakubo D, Nakayama T, Shirakawa AK, Jin Z, Yoshie O: Tax-inducible production of CC chemokine ligand 22 by human T cell leukemia virus type 1 (HTLV-1)-infected T cells promotes preferential transmission of HTLV-1 to CCR4-expressing CD4+ T cells. J Immunol; 2008 Jan 15;180(2):931-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tax-inducible production of CC chemokine ligand 22 by human T cell leukemia virus type 1 (HTLV-1)-infected T cells promotes preferential transmission of HTLV-1 to CCR4-expressing CD4+ T cells.
  • Adult T cell leukemia is a mature CD4+ T cell malignancy which predominantly expresses CCR4 and is etiologically associated with human T cell leukemia virus type 1 (HTLV-1).
  • Because HTLV-1 transmission depends on close cell-cell contacts, HTLV-1-infected T cells may preferentially interact with CCR4+CD4+ T cells for efficient viral transmission.
  • In terms of gene expression and protein secretion, we found a strong correlation between HTLV-1 Tax oncoprotein and CCL22, a CCR4 ligand, in HTLV-1-infected T cells.
  • Transient Tax expression in an HTLV-1-negative T cell line activated the CCL22 promoter and induced CCL22.
  • In chemotaxis assays, the culture supernatants of HTLV-1-infected T cells selectively attracted CCR4+CD4+ T cells in PBMCs.
  • Finally, anti-CCL22 Ab treatment also blocked HTLV-1 transmission to primary CD4+ T cells in coculture experiments with HTLV-1 producer cells.
  • Thus, HTLV-1-infected T cells produce CCL22 through Tax and selectively interact with CCR4+CD4+ T cells, resulting in preferential transmission of HTLV-1 to CCR4+CD4+ T cells.
  • [MeSH-major] CD4-Positive T-Lymphocytes / virology. Chemokine CCL22 / genetics. Gene Expression Regulation, Viral. Gene Products, tax / metabolism. Human T-lymphotropic virus 1 / physiology. Virus Internalization
  • [MeSH-minor] Cell Adhesion / drug effects. Cell Adhesion / genetics. Cell Line. Humans. Pertussis Toxin / pharmacology. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Receptors, CCR4 / antagonists & inhibitors. Receptors, CCR4 / metabolism. T-Lymphocytes / immunology. T-Lymphocytes / virology

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Immunol. 2008 Jun 15;180(12):8470
  • (PMID = 18178833.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL22 protein, human; 0 / CCR4 protein, human; 0 / Chemokine CCL22; 0 / Gene Products, tax; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, CCR4; EC 2.4.2.31 / Pertussis Toxin
  •  go-up   go-down


36. D'Agostino DM, Silic-Benussi M, Hiraragi H, Lairmore MD, Ciminale V: The human T-cell leukemia virus type 1 p13II protein: effects on mitochondrial function and cell growth. Cell Death Differ; 2005 Aug;12 Suppl 1:905-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The human T-cell leukemia virus type 1 p13II protein: effects on mitochondrial function and cell growth.
  • p13(II) of human T-cell leukemia virus type 1 (HTLV-1) is an 87-amino-acid protein that is targeted to the inner mitochondrial membrane. p13(II) alters mitochondrial membrane permeability, producing a rapid, membrane potential-dependent influx of K(+).
  • At the cellular level, p13(II) has been found to interfere with cell proliferation and transformation and to promote apoptosis induced by ceramide and Fas ligand.
  • Assays carried out in T cells (the major targets of HTLV-1 infection in vivo) demonstrate that p13(II)-mediated sensitization to Fas ligand-induced apoptosis can be blocked by an inhibitor of Ras farnesylation, thus implicating Ras signaling as a downstream target of p13(II) function.

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2003 May;4(5):373-84 [12728271.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 9;304(3):575-81 [12729592.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):6104-8 [12719519.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5141-9 [12910251.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31745-55 [12799372.001]
  • [Cites] FEBS Lett. 2003 Sep 18;552(1):28-34 [12972148.001]
  • [Cites] Hematol J. 2003;4(5):328-35 [14502257.001]
  • [Cites] Mol Genet Metab. 2003 Sep-Oct;80(1-2):11-26 [14567954.001]
  • [Cites] Adv Cancer Res. 2003;89:69-132 [14587871.001]
  • [Cites] J Virol. 2004 Feb;78(4):2142-51 [14747580.001]
  • [Cites] Nat Med. 2004 Feb;10(2):197-201 [14730358.001]
  • [Cites] J Gen Virol. 2004 Feb;85(Pt 2):451-61 [14769903.001]
  • [Cites] J Virol. 2004 Apr;78(8):3837-45 [15047799.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):15460-71 [14724286.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):14473-6 [14973134.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6629-34 [15100416.001]
  • [Cites] DNA Cell Biol. 2004 Apr;23(4):193-205 [15142377.001]
  • [Cites] J Virol. 2004 Jul;78(13):7199-207 [15194796.001]
  • [Cites] Science. 2004 Jul 30;305(5684):626-9 [15286356.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36803-8 [15201276.001]
  • [Cites] J Virol. 2004 Oct;78(20):11077-83 [15452228.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3618-22 [6304725.001]
  • [Cites] J Gen Virol. 1988 Jul;69 ( Pt 7):1695-710 [2899128.001]
  • [Cites] J Virol. 1992 Mar;66(3):1737-45 [1310774.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3005-9 [1348363.001]
  • [Cites] Virology. 1992 Jun;188(2):618-27 [1585637.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8813-7 [1528897.001]
  • [Cites] J Virol. 1993 Feb;67(2):1015-23 [8419636.001]
  • [Cites] J Virol. 1993 Mar;67(3):1218-26 [8437213.001]
  • [Cites] J Virol. 1993 Apr;67(4):2360-6 [8445734.001]
  • [Cites] J Virol. 1994 Oct;68(10):6778-81 [8084014.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11532-6 [7972096.001]
  • [Cites] J Virol. 1995 Mar;69(3):1907-12 [7853532.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):701-6 [7860146.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):111-5 [8552585.001]
  • [Cites] J Virol. 1997 Jan;71(1):75-83 [8985325.001]
  • [Cites] Int J Cancer. 1997 Apr 10;71(2):196-202 [9139842.001]
  • [Cites] Leukemia. 1997 Jun;11(6):866-70 [9177442.001]
  • [Cites] J Virol. 1997 Jul;71(7):5579-92 [9188632.001]
  • [Cites] Virology. 1997 Oct 13;237(1):123-8 [9344914.001]
  • [Cites] Virology. 1997 Oct 27;237(2):397-403 [9356350.001]
  • [Cites] Oncogene. 1997 Oct 16;15(16):1895-901 [9365235.001]
  • [Cites] J Virol. 1998 Mar;72(3):2554-9 [9499124.001]
  • [Cites] J Virol. 1998 May;72(5):4458-62 [9557741.001]
  • [Cites] Science. 1998 Jul 10;281(5374):266-9 [9657723.001]
  • [Cites] Acta Neuropathol. 1999 Feb;97(2):107-12 [9928820.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4505-14 [10442641.001]
  • [Cites] Oncogene. 1999 Sep 2;18(35):4930-9 [10490827.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1127-55 [10508231.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12039-43 [10518572.001]
  • [Cites] J Exp Med. 2001 Feb 19;193(4):509-19 [11181702.001]
  • [Cites] J Gen Virol. 1999 Dec;80 ( Pt 12):3257-65 [10567659.001]
  • [Cites] J Exp Med. 2000 Jan 3;191(1):33-46 [10620603.001]
  • [Cites] J Virol. 2000 Feb;74(3):1094-100 [10627519.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):E23-5 [10655597.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):567-72 [10662802.001]
  • [Cites] J Virol. 2000 Mar;74(6):2840-6 [10684300.001]
  • [Cites] Virology. 2000 Nov 10;277(1):127-35 [11062043.001]
  • [Cites] J Virol. 2000 Dec;74(23):11270-7 [11070026.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1787-95 [11080828.001]
  • [Cites] Cell Death Differ. 2000 Dec;7(12):1146-54 [11175251.001]
  • [Cites] Biochemistry. 2001 Apr 24;40(16):4893-903 [11305904.001]
  • [Cites] EMBO J. 2001 Aug 1;20(15):4107-21 [11483514.001]
  • [Cites] J Neurovirol. 2001 Feb;7(1):61-5 [11519484.001]
  • [Cites] J Virol. 2001 Oct;75(20):9885-95 [11559821.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3567-73 [11705878.001]
  • [Cites] J Virol. 2002 Feb;76(3):1400-14 [11773414.001]
  • [Cites] Trends Immunol. 2002 Jan;23(1):1-4 [11801441.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 19;1561(1):27-45 [11988179.001]
  • [Cites] J Virol. 2002 Aug;76(15):7843-54 [12097596.001]
  • [Cites] Eur J Biochem. 2002 Jul;269(14):3339-54 [12135472.001]
  • [Cites] Biochim Biophys Acta. 2002 Sep 2;1592(1):79-87 [12191770.001]
  • [Cites] J Virol. 2002 Oct;76(19):9806-18 [12208959.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Sep;66(3):396-406, table of contents [12208996.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):34424-33 [12093802.001]
  • [Cites] J Virol. 2002 Nov;76(21):10914-20 [12368334.001]
  • [Cites] Biochim Biophys Acta. 2002 Oct 11;1565(2):347-63 [12409206.001]
  • [Cites] FEBS Lett. 2003 Jan 30;535(1-3):34-8 [12560074.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5775-85 [12477721.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 28;303(1):1-7 [12646157.001]
  • [Cites] Virology. 2003 Mar 30;308(1):1-12 [12706085.001]
  • (PMID = 15761473.001).
  • [ISSN] 1350-9047
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 100730; United States / FIC NIH HHS / TW / TW005705-03; United States / FIC NIH HHS / TW / TW 05705; United States / FIC NIH HHS / TW / R03 TW005705; United States / FIC NIH HHS / TW / R03 TW005705-01A1; United States / FIC NIH HHS / TW / TW005705-01A1; United States / FIC NIH HHS / TW / TW005705-02; United States / FIC NIH HHS / TW / R03 TW005705-03; United States / FIC NIH HHS / TW / R03 TW005705-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Retroviridae Proteins; 0 / rof protein, Human T-lymphotropic virus 1; 0 / tof protein, Human T-lymphotropic virus 1; SY7Q814VUP / Calcium
  • [Number-of-references] 84
  • [Other-IDs] NLM/ NIHMS183534; NLM/ PMC3057663
  •  go-up   go-down


37. Lyell V, Khatamzas E, Allain T: Severe hypercalcaemia and lymphoma in an HTLV-1 positive Jamaican woman: a case report. J Med Case Rep; 2007;1:56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hypercalcaemia and lymphoma in an HTLV-1 positive Jamaican woman: a case report.
  • Human T cell lymphotrophic virus type-1 infection is endemic in the Afro-Caribbean community in Britain, with carriage rates of about 3%.
  • Although there is a long latency, carriers have a 1-5% chance of developing adult T cell leukaemia/lymphoma, a condition frequently complicated by marked and refractory hypercalcaemia, and with a poor prognosis.
  • We present the case of an elderly Jamaican woman with severe hypercalcaemia and a raised PTHrP who was found to have lymphoma and was positive for HTLV-1.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1999 Oct;84(10):3545-50 [10522993.001]
  • [Cites] BMJ. 2000 Mar 4;320(7235):611-2 [10698878.001]
  • [Cites] Endocr Relat Cancer. 2003 Sep;10(3):403-7 [14503917.001]
  • [Cites] Clin Lymphoma. 2004 Jun;5(1):29-36 [15245605.001]
  • [Cites] Am J Med Sci. 1995 Jun;309(6):312-4 [7771500.001]
  • [Cites] Am J Hematol. 2005 Mar;78(3):232-9 [15726602.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4467-70 [15930259.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):549-83 [16172192.001]
  • [Cites] J Natl Med Assoc. 1995 Oct;87(10):746-8 [7473848.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):2665-73 [15517871.001]
  • (PMID = 17651486.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1950877
  •  go-up   go-down


38. Schlecht-Louf G, Renard M, Mangeney M, Letzelter C, Richaud A, Ducos B, Bouallaga I, Heidmann T: Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc Natl Acad Sci U S A; 2010 Feb 23;107(8):3782-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we genetically "switched off' the envelope-mediated immunosuppression of an infectious retrovirus, the Friend murine leukemia virus, while preserving mutant envelope infectivity both ex vivo and in vivo, thus allowing us to test the functional importance of envelope-mediated immunosuppression in retrovirus physiology.
  • Remarkably, we show, in vivo, that the non-IS mutant virus displays the same propagation kinetics as its WT counterpart in irradiated immunocompromised mice but that it is rapidly and totally cleared from normal immunocompetent mice, which become fully protected against a challenge with the WT retrovirus.
  • Using cell depletion strategies, we further establish that envelope-mediated immunosuppression enables the retrovirus to escape innate (natural killer cells) and adaptive (CD8 T cells) antiviral effectors.
  • In conclusion, our work demonstrates the critical role of Env-induced immunosuppression for retrovirus propagation in vivo and identifies a unique definite target for antiretroviral therapies and vaccine strategies, also characterized in the human T-cell leukemia virus (HTLV) and xenotropic murine leukemia virus-related virus (XMRV) retroviruses, opening unprecedented prospects for the treatment of retroviral diseases.
  • [MeSH-major] Friend murine leukemia virus / immunology. Immune Tolerance. Leukemia, Experimental / immunology. Retroviridae Infections / immunology. Tumor Virus Infections / immunology. Viral Envelope Proteins / immunology. Virulence Factors / immunology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20534-9 [18077339.001]
  • [Cites] J Virol. 2007 Nov;81(22):12368-74 [17686853.001]
  • [Cites] J Virol. 2008 Apr;82(8):4135-48 [18272584.001]
  • [Cites] Cell Host Microbe. 2008 Jun 12;3(6):388-98 [18541215.001]
  • [Cites] Nat Rev Immunol. 2008 Dec;8(12):911-22 [18989317.001]
  • [Cites] Nat Rev Immunol. 2009 Jul;9(7):503-13 [19498380.001]
  • [Cites] J Immunol. 2009 Aug 1;183(3):1636-43 [19587016.001]
  • [Cites] Blood. 2009 Oct 8;114(15):3199-207 [19671923.001]
  • [Cites] J Gen Virol. 2001 Jul;82(Pt 7):1597-600 [11413370.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9226-30 [11459933.001]
  • [Cites] Annu Rev Immunol. 2002;20:621-67 [11861614.001]
  • [Cites] Science. 2002 Apr 19;296(5567):553-5 [11968185.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):13013-8 [14557543.001]
  • [Cites] J Virol. 2004 Jan;78(2):1050-4 [14694139.001]
  • [Cites] Immunity. 2004 Mar;20(3):293-303 [15030773.001]
  • [Cites] J Virol. 2004 Nov;78(21):11641-7 [15479805.001]
  • [Cites] Science. 1985 Oct 25;230(4724):453-5 [2996136.001]
  • [Cites] J Virol. 1990 May;64(5):2135-40 [2182908.001]
  • [Cites] J Virol. 1993 Aug;67(8):4533-42 [7687300.001]
  • [Cites] J Exp Med. 1995 Aug 1;182(2):477-86 [7629507.001]
  • [Cites] J Virol. 1996 Nov;70(11):7773-82 [8892898.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14920-5 [9843991.001]
  • [Cites] Mol Immunol. 2005 Feb;42(4):547-55 [15607812.001]
  • [Cites] J Virol. 2005 Aug;79(16):10619-26 [16051854.001]
  • [Cites] J Mol Biol. 2005 Oct 7;352(5):1029-34 [16140326.001]
  • [Cites] J Leukoc Biol. 2006 Jan;79(1):16-35 [16204622.001]
  • [Cites] J Immunol. 2006 Mar 15;176(6):3342-9 [16517701.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e25 [16609730.001]
  • [Cites] J Gen Virol. 2006 Jun;87(Pt 6):1423-38 [16690907.001]
  • [Cites] Immunol Rev. 2006 Aug;212:272-86 [16903920.001]
  • [Cites] Eur J Immunol. 2006 Oct;36(10):2658-70 [16981182.001]
  • [Cites] J Leukoc Biol. 2007 Jan;81(1):144-53 [16959895.001]
  • [Cites] Curr Opin Immunol. 2008 Feb;20(1):30-8 [18206359.001]
  • (PMID = 20142478.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Viral Envelope Proteins; 0 / Viral Vaccines; 0 / Virulence Factors
  • [Other-IDs] NLM/ PMC2840525
  •  go-up   go-down


39. Miyamura F, Kako S, Yamagami H, Sato K, Sato M, Terasako K, Kimura S, Nakasone H, Aoki S, Okuda S, Yamazaki R, Oshima K, Yoshinaga K, Higuchi T, Nishida J, Demitsu T, Kakehashi A, Kanda Y: Successful treatment of young-onset adult T cell leukemia/lymphoma and preceding chronic refractory eczema and corneal injury by allogeneic hematopoietic stem cell transplantation. Int J Hematol; 2009 Oct;90(3):397-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of young-onset adult T cell leukemia/lymphoma and preceding chronic refractory eczema and corneal injury by allogeneic hematopoietic stem cell transplantation.
  • Only some carriers of human T cell lymphotropic virus type I (HTLV-1) develop adult T cell leukemia/lymphoma (ATLL) after a long latency period, and an association has been reported between chronic refractory eczema, known as infective dermatitis, and young-onset ATLL.
  • A 25-year-old female developed ATLL and underwent allogeneic hematopoietic stem cell transplantation (HSCT) in non-remission.
  • She had chronic refractory eczema and corneal injury at the onset of ATLL.
  • Remission of ATLL was achieved, and the HTLV-1 proviral load decreased after HSCT.
  • More than a year has passed since the transplantation was performed, and she has had no recurrence of either ATLL or lesions in the skin and eye.
  • Her clinical course suggests a possible association between skin and eye lesions and HTLV-1 infection.
  • Special attention is needed when HTLV-1 carriers develop eye or skin lesions.
  • [MeSH-major] Corneal Diseases / therapy. Eczema / therapy. Hematopoietic Stem Cell Transplantation. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Chronic Disease. Female. HTLV-I Infections / complications. Human T-lymphotropic virus 1. Humans. Transplantation, Homologous. Treatment Outcome. Viral Load


40. Nicot C, Harrod RL, Ciminale V, Franchini G: Human T-cell leukemia/lymphoma virus type 1 nonstructural genes and their functions. Oncogene; 2005 Sep 5;24(39):6026-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T-cell leukemia/lymphoma virus type 1 nonstructural genes and their functions.
  • The human T-cell leukemia/lymphoma virus (HTLV) genome, in addition to the structural Gag and Env proteins and retroviral enzymes, carries a region at its 3' end originally designated pX.
  • To date, we know that this region encodes two essential transcriptional and post-transcriptional positive regulators of viral expression, the Tax and Rex proteins, respectively (reviewed elsewhere in this issue).
  • [MeSH-major] Human T-lymphotropic virus 1 / genetics. Viral Nonstructural Proteins / genetics

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155609.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI058944; United States / NCI NIH HHS / CA / R01 CA106258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Viral Nonstructural Proteins
  • [Number-of-references] 54
  •  go-up   go-down


41. Patronas M, Smith JA, Levy-Clarke GA, Reed GF, Buggage RR: Hypergammaglobulinemia and corneal opacities in patients with human T-cell lymphotrophic virus type-1. Am J Ophthalmol; 2006 Dec;142(6):1088-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypergammaglobulinemia and corneal opacities in patients with human T-cell lymphotrophic virus type-1.
  • PURPOSE: To investigate the relationship between serum immunoglobulin levels and corneal opacities in a cohort of patients with human T-cell lymphotrophic virus type-1 (HTLV-1).
  • METHODS: Complete ophthalmologic examination was performed on 44 patients with HTLV-1 infection (25 patients with adult T-cell leukemia/lymphoma [ATL], 18 patients with HTLV-1 that was associated myelopathy/tropical spastic paraparesis [HAM/TSP], and one patient who was asymptomatic).
  • RESULTS: Corneal opacities were identified in 15 of 25 patients (60%) with ATL and five of 18 patients (28%) with HAM/TSP.
  • The prevalence of corneal opacities was associated statistically with elevated IgG level (P = .023) in patients with ATL, but not in patients with HAM/TSP (P > .99).
  • CONCLUSION: Although the mechanism remains unclear, hypergammaglobulinemia is associated with the development of the corneal opacities in patients of African descent with ATL.
  • [MeSH-major] Corneal Opacity / etiology. HTLV-I Infections / complications. Hypergammaglobulinemia / etiology
  • [MeSH-minor] Human T-lymphotropic virus 1 / isolation & purification. Humans. Immunoglobulin A / blood. Immunoglobulin G / blood. Immunoglobulin M / blood. Nephelometry and Turbidimetry. Prevalence. Retrospective Studies

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157606.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


42. Wada T, Yoshinaga E, Oiso N, Kawara S, Kawada A, Kozuka T: Adult T-cell leukemia-lymphoma associated with follicular mucinosis. J Dermatol; 2009 Dec;36(12):638-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia-lymphoma associated with follicular mucinosis.
  • Follicular mucinosis (alopecia mucinosa) is often associated with malignancies including mycosis fungoides and Sézary syndrome, but not adult T-cell leukemia-lymphoma (ATLL).
  • The patient showed 11% of flower-shaped atypical lymphocytes in blood examination and positive human T-cell leukemia virus type 1 antibody in serology, consistent with the chronic type of ATLL.
  • This case seems to be a very rare association of follicular mucinosis and chronic ATLL, suggesting that malignant T cells may have a feature of folliculotropism as well as epidermotropism.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / complications. Mucinosis, Follicular / complications
  • [MeSH-minor] DNA, Viral / genetics. DNA, Viral / isolation & purification. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / isolation & purification. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958447.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


43. Ohkura S, Yamashita M, Ishida T, Babu PG, Koyanagi Y, Yamamoto N, Miura T, Hayami M: Phylogenetic heterogeneity of new HTLV type 1 isolates from southern India in subgroup A. AIDS Res Hum Retroviruses; 2005 Apr;21(4):325-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phylogenetic heterogeneity of new HTLV type 1 isolates from southern India in subgroup A.
  • Seven isolates of human T cell leukemia virus type 1 (HTLV-1) were taken in southern India and phylogenetically analyzed to gain new insights into the origin and dissemination of HTLV-1 in the subcontinent.
  • The new Indian HTLV-1s were found to be members of subgroup A (Transcontinental subgroup) of the Cosmopolitan group.
  • These results demonstrate that Indian HTLV-1s are genetically heterogeneous and include the most divergent strain of subgroup A.
  • On the basis of these results, we speculate that subgroup A HTLV- 1s may have been present for thousands of years in India.
  • [MeSH-major] HTLV-I Infections / virology. Human T-lymphotropic virus 1 / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adult. Child. DNA, Viral / chemistry. Female. Humans. India. Male. Middle Aged. Molecular Sequence Data. Phylogeny. Sequence Analysis, DNA. Terminal Repeat Sequences / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943577.001).
  • [ISSN] 0889-2229
  • [Journal-full-title] AIDS research and human retroviruses
  • [ISO-abbreviation] AIDS Res. Hum. Retroviruses
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY607576/ AY607577/ AY607578/ AY607579/ AY607580/ AY607581/ AY607582
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


44. Pikalova Z, Szotkowski T, Indrak K: Immunophenotyping--a tool for the differential diagnostics of lymphadenomegaly. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun;151(1):99-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Flow cytometry is a method that enables the automated quantification of a set of parameters for a large number of cells or cell-like particles.
  • It is also possible to analyze solid tissues after reduction to a single cell suspension.
  • CONCLUSIONS: The authors demonstrate fl ow cytometry as a relatively less common but efficient way of lymph node assessment in a patient with an anamnesis of acute lymphoblastic leukemia.
  • [MeSH-major] Immunophenotyping. Leukemia / diagnosis. Lymph Nodes / immunology
  • [MeSH-minor] Adult. Diagnosis, Differential. Flow Cytometry. Humans. Lymphatic Diseases / diagnosis. Male

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690749.001).
  • [ISSN] 1213-8118
  • [Journal-full-title] Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
  • [ISO-abbreviation] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


45. Kim HS, Kim KH, Kim KH, Chang MH, Ji SH, Lim DH, Kim K, Kim SJ, Ko Y, Ki CS, Jo SJ, Lee JW, Kim WS: Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma; 2009 May;50(5):757-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma.
  • We investigated the value of Epstein-Barr virus (EBV) DNA load in unfractionated whole blood for the diagnosis and prognosis of EBV-associated lymphoma.
  • From July 2004 to July 2007, we compared EBV DNA loads in 101 patients with lymphoma and 105 control individuals.
  • The median copy number of EBV was higher in patients with EBV-positive lymphoma (p<0.001).
  • In patients with natural killer (NK)/T-cell lymphomas, the median EBV DNA load at presentation was significantly related to the stage (p = 0.011) and response (p = 0.026).
  • The newly proposed classification model for NK/T cell lymphoma showed EBV DNA load differed significantly between patients with upper and extra-upper aerodigestive tracts (p = 0.017).
  • In 16 patients with NK/T-cell lymphoma monitored serially, EBV DNA load correlated well with the treatment response and clinical course.
  • [MeSH-major] DNA, Viral / blood. Epstein-Barr Virus Infections / diagnosis. Herpesvirus 4, Human / isolation & purification. Lymphoma, Extranodal NK-T-Cell / diagnosis. Severity of Illness Index
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Gastrointestinal Tract / virology. Humans. Male. Middle Aged. Prognosis. Viral Load. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 May;50(5):684-6 [19330650.001]
  • (PMID = 19330658.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


46. Gupta M, Ashok Kumar J, Sitaram U, Neeraj S, Nancy A, Balasubramanian P, Abraham A, Mathews V, Viswabandya A, George B, Chandy M, Srivastava A, Srivastava VM: The t(6;9)(p22;q34) in myeloid neoplasms: a retrospective study of 16 cases. Cancer Genet Cytogenet; 2010 Dec;203(2):297-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among patients with acute myeloid leukemia (AML), the t(6;9) (p22;q34) is a rare but defined subset with a poor prognosis.
  • We report 16 patients with the t(6;9), of whom 13 had AML, 2 had myelodysplastic syndrome (MDS), and 1 had chronic myeloid leukemia in myeloid blast crisis (CML-BC).
  • All except for one were evaluated at diagnosis.
  • HLA-DR was positive in all 12 patients assessed, CD33 in 11, CD13 in 10, and CD34 in seven.
  • Four patients had one other abnormality apart from the t(6;9).
  • The only patients who survived were three out of the four who had allogeneic hematopoietic stem cell transplantation (HSCT).
  • [MeSH-major] Chromosomes, Human, Pair 6. Chromosomes, Human, Pair 9. Leukemia, Myeloid / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Child. Female. Hematopoietic Stem Cell Transplantation. Humans. Karyotyping. Male. Middle Aged. Mutation. Retrospective Studies. Transplantation, Homologous

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21156248.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Mokrzycka M, Pawlik A, Kałdońska M, Millo B: Assessment of liver function in children with acute lymphoblastic leukemia in remission. Ann Acad Med Stetin; 2006;52(3):61-5; discussion 65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of liver function in children with acute lymphoblastic leukemia in remission.
  • PURPOSE: Acute lymphoblastic leukemia (ALL) is the most common malignant neoplasm in children.
  • [MeSH-major] Liver Function Tests. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Adolescent. Adult. Area Under Curve. Child. Diagnosis, Differential. Female. Half-Life. Hepatitis, Chronic / complications. Hepatitis, Chronic / diagnosis. Humans. Lidocaine / analogs & derivatives. Lidocaine / pharmacokinetics. Liver / metabolism. Male. Reference Values. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Liver Function Tests.
  • Hazardous Substances Data Bank. LIDOCAINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17385349.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 7728-40-7 / monoethylglycinexylidide; 98PI200987 / Lidocaine
  •  go-up   go-down


48. Hidaka T, Nakahata S, Hatakeyama K, Hamasaki M, Yamashita K, Kohno T, Arai Y, Taki T, Nishida K, Okayama A, Asada Y, Yamaguchi R, Tsubouchi H, Yokota J, Taniwaki M, Higashi Y, Morishita K: Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma. Blood; 2008 Jul 15;112(2):383-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATLL) is caused by latent human T-lymphotropic virus-1 (HTLV-1) infection.
  • To clarify the molecular mechanism underlying leukemogenesis after viral infection, we precisely mapped 605 chromosomal breakpoints in 61 ATLL cases by spectral karyotyping and identified frequent chromosomal breakpoints in 10p11, 14q11, and 14q32.
  • Single nucleotide polymorphism (SNP) array-comparative genomic hybridization (CGH), genetic, and expression analyses of the genes mapped within a common breakpoint cluster region in 10p11.2 revealed that in ATLL cells, transcription factor 8 (TCF8) was frequently disrupted by several mechanisms, including mainly epigenetic dysregulation.
  • TCF8 mutant mice frequently developed invasive CD4(+) T-cell lymphomas in the thymus or in ascitic fluid in vivo.
  • Down-regulation of TCF8 expression in ATLL cells in vitro was associated with resistance to transforming growth factor beta1 (TGF-beta1), a well-known characteristic of ATLL cells, suggesting that escape from TGF-beta1-mediated growth inhibition is important in the pathogenesis of ATLL.
  • These findings indicate that TCF8 has a tumor suppressor role in ATLL.
  • [MeSH-major] Homeodomain Proteins / physiology. Leukemia-Lymphoma, Adult T-Cell / etiology. Transcription Factors / physiology. Transforming Growth Factor beta1 / physiology
  • [MeSH-minor] Animals. Chromosome Breakage. Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 14. Down-Regulation / genetics. Humans. Karyotyping. Mice. Tumor Cells, Cultured

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467597.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / ZEB1 protein, human
  •  go-up   go-down


49. Van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G, Panzer-Grümayer ER, Schrappe M, Schrauder A, Meyer C, Marschalek R, Nigro LL, Metzler M, Basso G, Mann G, Den Boer ML, Biondi A, Pieters R, Van Dongen JJ, Interfant-99 Study Group: Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia; 2009 Jun;23(6):1073-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
  • Acute lymphoblastic leukemia (ALL) in infants younger than 1 year is a rare but relatively homogeneous disease ( approximately 80% MLL gene rearranged, approximately 70% CD10-negative) when compared with childhood and adult ALL.
  • Several studies in children and adults with ALL have shown that minimal residual disease (MRD) status is a strong and independent prognostic factor.
  • MRD was analyzed by real-time quantitative PCR analysis of rearranged immunoglobulin genes, T-cell receptor genes and MLL genes at various time points (TP) during therapy.
  • Higher MRD levels at the end of induction (TP2) and consolidation (TP3) were significantly associated with lower disease-free survival.
  • Comparison between the current Interfant-06 stratification at diagnosis and the here presented MRD-based stratification showed that both stratifications recognized different subgroups of patients.
  • [MeSH-major] Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Follow-Up Studies. Gene Rearrangement. Genes, Immunoglobulin. Histone-Lysine N-Methyltransferase. Humans. Infant. Infant, Newborn. Myeloid-Lymphoid Leukemia Protein / genetics. Polymerase Chain Reaction. Prognosis. Receptors, Antigen, T-Cell / genetics. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212338.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300130
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Receptors, Antigen, T-Cell; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Investigator] Pieters R; de Rossi G; Biondi A; Suppiah R; Felice M; Mann G; Schrappe M; Janka-Schaub G; Stary J; Silverman L; Fester A; Mechinaud F; Li CK; Hovi L; Campbell M; Szczepañski T; Rubnitz JE; Hann I; Vora A
  •  go-up   go-down


50. Javier RT: Cell polarity proteins: common targets for tumorigenic human viruses. Oncogene; 2008 Nov 24;27(55):7031-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell polarity proteins: common targets for tumorigenic human viruses.
  • Loss of polarity and disruption of cell junctions are common features of epithelial-derived cancer cells, and mounting evidence indicates that such defects have a direct function in the pathology of cancer.
  • Supporting this idea, results with several different human tumor viruses indicate that their oncogenic potential depends in part on a common ability to inactivate key cell polarity proteins.
  • For example, adenovirus (Ad) type 9 is unique among human Ads by causing exclusively estrogen-dependent mammary tumors in experimental animals and in having E4 region-encoded open reading frame 1 (E4-ORF1) as its primary oncogenic determinant.
  • Most notably, the E4-ORF1 PBM mediates interactions with a selected group of cellular PDZ proteins, three of which include the cell polarity proteins Dlg1, PATJ and ZO-2.
  • Data further indicate that these interactions promote disruption of cell junctions and a loss of cell polarity.
  • In addition, one or more of the E4-ORF1-interacting cell polarity proteins, as well as the cell polarity protein Scribble, are common targets for the high-risk human papillomavirus (HPV) E6 or human T-cell leukemia virus type 1 (HTLV-1) Tax oncoproteins.
  • Underscoring the significance of these observations, in humans, high-risk HPV and HTLV-1 are causative agents for cervical cancer and adult T-cell leukemia, respectively.
  • Consequently, human tumor viruses should serve as powerful tools for deciphering mechanisms whereby disruption of cell junctions and loss of cell polarity contribute to the development of many human cancers.
  • This review article discusses evidence supporting this hypothesis, with an emphasis on the human Ad E4-ORF1 oncoprotein.
  • [MeSH-major] Cell Polarity. Membrane Proteins / physiology. Neoplasms / etiology. Virus Attachment. Virus Diseases / complications
  • [MeSH-minor] Adenovirus Infections, Human / virology. Adenoviruses, Human / physiology. Animals. Cell Transformation, Viral / physiology. Gene Products, tax / physiology. Human T-lymphotropic virus 1 / metabolism. Human T-lymphotropic virus 1 / physiology. Human papillomavirus 6 / metabolism. Human papillomavirus 6 / physiology. Humans. Models, Biological. Oncogene Proteins, Viral / metabolism. Oncogene Proteins, Viral / physiology. Protein Binding

  • MedlinePlus Health Information. consumer health - Viral Infections.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):12974-82 [11150294.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] Cell. 2001 Aug 24;106(4):489-98 [11525734.001]
  • [Cites] J Cell Sci. 2001 Jul;114(Pt 13):2375-82 [11559746.001]
  • [Cites] Oncogene. 2001 Sep 6;20(39):5431-9 [11571640.001]
  • [Cites] J Cell Sci. 2001 Sep;114(Pt 18):3219-31 [11591811.001]
  • [Cites] EMBO J. 2001 Oct 15;20(20):5578-86 [11598001.001]
  • [Cites] Curr Biol. 2001 Dec 11;11(24):1958-62 [11747822.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7874-87 [11753670.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):455-61 [11689568.001]
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):39-50 [11801722.001]
  • [Cites] Biochem J. 2002 Feb 1;361(Pt 3):525-36 [11802782.001]
  • [Cites] J Gen Virol. 2002 Feb;83(Pt 2):283-9 [11807220.001]
  • [Cites] J Virol. 2002 Mar;76(6):2648-53 [11861831.001]
  • [Cites] Genes Dev. 2002 Mar 15;16(6):693-706 [11914275.001]
  • [Cites] Steroids. 2002 May;67(6):471-5 [11960623.001]
  • [Cites] Exp Cell Res. 2002 May 1;275(2):155-70 [11969287.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Apr;80(4-5):369-81 [11983484.001]
  • [Cites] Science. 2002 May 31;296(5573):1642-4 [12040178.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):30183-90 [12042308.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30928-34 [12050163.001]
  • [Cites] J Cell Biol. 2002 Sep 2;158(5):967-78 [12196510.001]
  • [Cites] Oncogene. 2002 Nov 21;21(53):8140-8 [12444549.001]
  • [Cites] Nature. 2002 Dec 12;420(6916):629-35 [12478284.001]
  • [Cites] Curr Opin Cell Biol. 2003 Feb;15(1):67-72 [12517706.001]
  • [Cites] J Cell Biol. 2003 Feb 3;160(3):423-32 [12566432.001]
  • [Cites] Oncogene. 2003 Feb 6;22(5):710-21 [12569363.001]
  • [Cites] J Virol. 2003 Mar;77(5):2807-18 [12584304.001]
  • [Cites] Nature. 2003 Feb 13;421(6924):753-6 [12610628.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Mar;4(3):225-36 [12612641.001]
  • [Cites] Breast Cancer Res. 2003;5(2):117-9 [12631393.001]
  • [Cites] Development. 2003 May;130(9):1927-35 [12642496.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):322-6 [12646923.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1090-100 [12695331.001]
  • [Cites] Curr Top Microbiol Immunol. 2003;272:287-330 [12747554.001]
  • [Cites] Bioessays. 2003 Jun;25(6):542-53 [12766944.001]
  • [Cites] J Virol. 1987 Feb;61(2):543-52 [2949089.001]
  • [Cites] Nature. 1987 Apr 16-22;326(6114):714-7 [3031513.001]
  • [Cites] J Virol. 1989 Feb;63(2):631-8 [2911117.001]
  • [Cites] J Natl Cancer Inst. 1989 Feb 15;81(4):294-8 [2913327.001]
  • [Cites] J Virol. 1989 Jun;63(6):2605-15 [2724411.001]
  • [Cites] Dev Biol. 1989 Jul;134(1):222-35 [2471660.001]
  • [Cites] Genes Dev. 1989 Nov;3(11):1699-710 [2532611.001]
  • [Cites] Virology. 1990 Feb;174(2):345-53 [2137659.001]
  • [Cites] Nucleic Acids Res. 1990 May 25;18(10):3065-6 [2349112.001]
  • [Cites] Virology. 1990 Aug;177(2):419-26 [2142553.001]
  • [Cites] Pathol Res Pract. 1990 Aug;186(4):427-38 [2174150.001]
  • [Cites] J Virol. 1991 Jun;65(6):3192-202 [2033670.001]
  • [Cites] Cell. 1991 Aug 9;66(3):451-64 [1651169.001]
  • [Cites] Adv Cancer Res. 1991;57:47-85 [1835254.001]
  • [Cites] J Virol. 1992 Jul;66(7):4606-11 [1534854.001]
  • [Cites] Science. 1992 Aug 28;257(5074):1267-71 [1519063.001]
  • [Cites] J Cell Biol. 1994 Mar;124(6):949-61 [8132716.001]
  • [Cites] J Virol. 1994 Jun;68(6):3917-24 [8189528.001]
  • [Cites] J Neurosci. 1995 Mar;15(3 Pt 2):2354-66 [7891172.001]
  • [Cites] Science. 1995 Apr 21;268(5209):411-5 [7536343.001]
  • [Cites] Science. 1995 Sep 22;269(5231):1737-40 [7569905.001]
  • [Cites] Nature. 1995 Nov 2;378(6552):85-8 [7477295.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):641-9 [8573338.001]
  • [Cites] J Virol. 1996 Feb;70(2):862-72 [8551625.001]
  • [Cites] Science. 1996 May 17;272(5264):1020-3 [8638125.001]
  • [Cites] Science. 1996 Jun 7;272(5267):1470-3 [8633237.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(1):57-67 [8738606.001]
  • [Cites] Structure. 1996 Sep 15;4(9):1077-92 [8805593.001]
  • [Cites] J Biol Chem. 1996 Oct 18;271(42):25723-6 [8824195.001]
  • [Cites] J Cell Biol. 1996 Sep;134(6):1469-82 [8830775.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11295-301 [8876129.001]
  • [Cites] Neuron. 1996 Oct;17(4):575-8 [8893015.001]
  • [Cites] Curr Opin Neurobiol. 1996 Oct;6(5):602-8 [8937823.001]
  • [Cites] Science. 1997 Jan 3;275(5296):73-7 [8974395.001]
  • [Cites] Trends Biochem Sci. 1996 Dec;21(12):455-8 [9009824.001]
  • [Cites] J Virol. 1997 Mar;71(3):1857-70 [9032316.001]
  • [Cites] Curr Biol. 2003 Sep 2;13(17):R661-2 [12956964.001]
  • [Cites] Nat Cell Biol. 2003 Nov;5(11):987-93 [14562058.001]
  • [Cites] Science. 2003 Nov 14;302(5648):1227-31 [14551319.001]
  • [Cites] J Cell Sci. 2003 Dec 15;116(Pt 24):4925-34 [14625386.001]
  • [Cites] J Virol. 1997 Oct;71(10):7873-80 [9311876.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11612-6 [9326658.001]
  • [Cites] Genes Dev. 1997 Oct 1;11(19):2532-44 [9334318.001]
  • [Cites] Oncogene. 1998 Feb 5;16(5):643-54 [9482110.001]
  • [Cites] J Virol. 1999 Dec;73(12):10095-103 [10559324.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):5967-72 [10557085.001]
  • [Cites] Oncogene. 2000 Jan 20;19(3):365-72 [10656683.001]
  • [Cites] J Virol. 2000 Mar;74(5):2084-93 [10666238.001]
  • [Cites] Oncogene. 2000 Feb 10;19(6):719-25 [10698489.001]
  • [Cites] Nature. 2000 Apr 13;404(6779):782-7 [10783894.001]
  • [Cites] J Virol. 2000 Jun;74(11):5168-81 [10799592.001]
  • [Cites] Nat Cell Biol. 2000 Aug;2(8):531-9 [10934474.001]
  • [Cites] J Cell Biochem. 2000 Aug 2;79(2):213-24 [10967549.001]
  • [Cites] Semin Cell Dev Biol. 2000 Aug;11(4):315-24 [10966866.001]
  • [Cites] J Virol. 2000 Oct;74(20):9680-93 [11000240.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 2;1493(3):319-24 [11018256.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(21):8244-53 [11027293.001]
  • [Cites] Oncogene. 2000 Nov 2;19(46):5270-80 [11077444.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1661-8 [11080807.001]
  • [Cites] J Virol. 2001 Jan;75(2):557-68 [11134268.001]
  • [Cites] Oncogene. 2000 Nov 30;19(51):5884-91 [11127819.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):136-41 [11134523.001]
  • [Cites] J Virol. 2001 Apr;75(7):3089-94 [11238835.001]
  • [Cites] Mol Cell Biol. 2001 Mar;21(5):1475-83 [11238884.001]
  • [Cites] Front Biosci. 2005;10:1106-17 [15769610.001]
  • [Cites] EMBO J. 2005 Mar 23;24(6):1211-21 [15775987.001]
  • [Cites] Development. 2005 May;132(10):2273-85 [15829519.001]
  • [Cites] Cell. 2005 May 6;121(3):451-63 [15882626.001]
  • [Cites] Immunity. 2005 Jun;22(6):737-48 [15963788.001]
  • [Cites] Oncogene. 2005 Jun 23;24(27):4330-9 [15806148.001]
  • [Cites] Blood. 2005 Aug 1;106(3):988-95 [15831709.001]
  • [Cites] J Biol Chem. 2005 Aug 12;280(32):28936-43 [15951562.001]
  • [Cites] Kidney Int. 2005 Sep;68(3):955-65 [16105026.001]
  • [Cites] Cell Cycle. 2005 Jul;4(7):883-8 [15970698.001]
  • [Cites] J Cell Sci. 2005 Sep 1;118(Pt 17):4049-57 [16129888.001]
  • [Cites] Retrovirology. 2005;2:46 [16042787.001]
  • [Cites] J Cell Sci. 2005 Sep 15;118(Pt 18):4283-93 [16141229.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25408-15 [11964389.001]
  • [Cites] Nature. 2002 Jul 18;418(6895):348-52 [12124628.001]
  • [Cites] J Neurosci. 2002 Aug 1;22(15):6415-25 [12151521.001]
  • [Cites] J Cell Biol. 2005 Sep 12;170(6):895-901 [16157700.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8266-73 [16166303.001]
  • [Cites] Breast Cancer Res. 2005;7(5):190-7 [16168137.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7686-96 [16299529.001]
  • [Cites] J Cell Biol. 2005 Dec 19;171(6):1061-71 [16344308.001]
  • [Cites] Mol Biol Cell. 2006 Feb;17(2):966-76 [16339077.001]
  • [Cites] J Biol Chem. 2006 Feb 17;281(7):4267-73 [16332687.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1980-8 [16263794.001]
  • [Cites] J Cell Sci. 2006 Mar 15;119(Pt 6):979-87 [16525119.001]
  • [Cites] EMBO J. 2006 Mar 22;25(6):1406-17 [16511562.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1121-3 [16564003.001]
  • [Cites] J Med Virol. 2006 Apr;78(4):501-7 [16482544.001]
  • [Cites] J Androl. 2006 May-Jun;27(3):390-404 [16452527.001]
  • [Cites] Mol Biol Cell. 2006 May;17(5):2303-11 [16525015.001]
  • [Cites] J Virol. 2006 Jun;80(11):5301-7 [16699010.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):197-8 [16807799.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47 [16807803.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):261-72 [16807805.001]
  • [Cites] Nat Rev Genet. 2006 Aug;7(8):606-19 [16847462.001]
  • [Cites] Oncogene. 2006 Jul 20;25(31):4276-85 [16532034.001]
  • [Cites] J Virol. 2003 Jun;77(12):6957-64 [12768014.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(12):4267-82 [12773569.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2003 Feb;49(1):13-21 [12839333.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3735-42 [12839967.001]
  • [Cites] Retrovirology. 2006;3:71 [17042961.001]
  • [Cites] Nat Cell Biol. 2006 Nov;8(11):1235-45 [17060907.001]
  • [Cites] Trends Cell Biol. 2006 Dec;16(12):622-30 [17067797.001]
  • [Cites] Retrovirology. 2006;3:88 [17140451.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):8970-81 [14645510.001]
  • [Cites] Curr Top Microbiol Immunol. 2004;273:163-214 [14674602.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):194-9 [14710229.001]
  • [Cites] Exp Cell Res. 2004 Jan 1;292(1):51-66 [14720506.001]
  • [Cites] Virology. 2004 Jan 5;318(1):327-36 [14972558.001]
  • [Cites] J Biol Chem. 2004 Mar 12;279(11):10157-66 [14699157.001]
  • [Cites] Virology. 2004 Mar 1;320(1):52-62 [15003862.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):19051-63 [14960569.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):336-61 [15129647.001]
  • [Cites] J Cell Biol. 2004 Jul 19;166(2):173-8 [15263016.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1909-25 [15314019.001]
  • [Cites] Oncogene. 2004 Oct 21;23(49):8033-9 [15378012.001]
  • [Cites] J Virol. 2004 Nov;78(22):12366-77 [15507623.001]
  • [Cites] Int J Cancer. 1974 Mar 15;13(3):286-90 [4822103.001]
  • [Cites] Virology. 1979 Mar;93(2):481-92 [452413.001]
  • [Cites] Virology. 1980 Sep;105(2):537-50 [7423858.001]
  • [Cites] Nucleic Acids Res. 1981 Aug 25;9(16):4023-42 [6985482.001]
  • [Cites] Virology. 1983 Jul 30;128(2):377-90 [6310863.001]
  • [Cites] J Virol. 1985 Oct;56(1):250-7 [4032537.001]
  • [Cites] Cancer Surv. 1986;5(2):389-404 [2946407.001]
  • [Cites] J Virol. 2007 Nov;81(21):11900-7 [17715223.001]
  • [Cites] J Biol Chem. 2007 Nov 9;282(45):33132-41 [17855372.001]
  • [Cites] Science. 2008 Feb 22;319(5866):1096-100 [18202256.001]
  • [Cites] Oncogene. 2008 Feb 28;27(10):1412-20 [17828302.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1285-90 [16619250.001]
  • [Cites] Cell. 2006 Aug 25;126(4):741-54 [16923393.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:207-35 [16771626.001]
  • [Cites] Nat Immunol. 2006 Nov;7(11):1143-9 [17053799.001]
  • [Cites] Curr Biol. 2006 Dec 19;16(24):2395-405 [17081755.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19872-7 [17172448.001]
  • [Cites] J Biol Chem. 2007 Jan 5;282(1):65-71 [17085449.001]
  • [Cites] Neoplasia. 2006 Dec;8(12):1019-27 [17217619.001]
  • [Cites] Nat Immunol. 2007 Feb;8(2):154-61 [17187070.001]
  • [Cites] Nat Immunol. 2007 Feb;8(2):126-7 [17242684.001]
  • [Cites] EMBO Rep. 2007 Feb;8(2):158-64 [17235357.001]
  • [Cites] J Neurochem. 2007 Feb;100(4):1032-46 [17156128.001]
  • [Cites] J Biol Chem. 2007 Feb 9;282(6):4162-71 [17145756.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):5085-99 [17170109.001]
  • [Cites] Genes Cells. 2007 Feb;12(2):219-33 [17295841.001]
  • [Cites] J Neurosci. 2007 Feb 14;27(7):1682-91 [17301176.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1626-35 [17308103.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):483-96 [17344411.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] J Cell Biol. 2007 Mar 26;176(7):1035-47 [17371830.001]
  • [Cites] J Virol. 2007 Apr;81(8):4080-90 [17287269.001]
  • [Cites] Genes Cells. 2007 Apr;12(4):473-86 [17397395.001]
  • [Cites] Genes Cells. 2007 Apr;12(4):535-46 [17397400.001]
  • [Cites] Oncogene. 2007 Apr 5;26(16):2272-82 [17043654.001]
  • [Cites] Dev Cell. 2007 Apr;12(4):487-502 [17419990.001]
  • [Cites] J Virol. 2007 May;81(9):4787-97 [17314165.001]
  • [Cites] Development. 2007 May;134(9):1799-807 [17435047.001]
  • [Cites] Exp Cell Res. 2007 May 1;313(8):1533-47 [17374535.001]
  • [Cites] Mol Biol Cell. 2007 May;18(5):1744-55 [17332497.001]
  • [Cites] Trends Immunol. 2007 May;28(5):196-200 [17395537.001]
  • [Cites] J Cell Biol. 2007 Jun 4;177(5):893-903 [17548515.001]
  • [Cites] Nat Cell Biol. 2007 Sep;9(9):1016-24 [17762893.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1206-11 [9037031.001]
  • [Cites] Mech Dev. 1997 Mar;62(2):161-74 [9152008.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6670-5 [9192623.001]
  • [Cites] FEBS Lett. 1997 Aug 18;413(2):243-8 [9280290.001]
  • [Cites] Oncogene. 2008 Nov 24;27(55):7018-30 [19029942.001]
  • [Cites] J Virol. 1992 Oct;66(10):5867-78 [1326648.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7834-8 [8395056.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5624-8 [8242616.001]
  • [Cites] J Cell Sci. 1998 Apr;111 ( Pt 8):1071-80 [9512503.001]
  • [Cites] J Cell Biol. 1998 Apr 6;141(1):199-208 [9531559.001]
  • [Cites] J Cell Sci. 1998 Aug;111 ( Pt 16):2365-76 [9683631.001]
  • [Cites] J Virol. 1999 Feb;73(2):1591-600 [9882365.001]
  • [Cites] Ultrastruct Pathol. 1998 Nov-Dec;22(6):413-20 [9891919.001]
  • [Cites] Dev Biol. 1999 Feb 1;206(1):88-99 [9918697.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):9-17 [9926915.001]
  • [Cites] J Cell Physiol. 1999 Feb;178(2):235-46 [10048588.001]
  • [Cites] J Virol. 1999 Apr;73(4):3071-9 [10074157.001]
  • [Cites] Int J Cancer. 1999 Jul 2;82(1):137-44 [10360833.001]
  • [Cites] Carcinogenesis. 1999 Aug;20(8):1425-31 [10426787.001]
  • [Cites] Int J Cancer. 1999 Oct 29;83(3):349-58 [10495427.001]
  • [Cites] Oncogene. 1999 Sep 30;18(40):5487-96 [10523825.001]
  • [Cites] Science. 1962 Sep 14;137(3533):835-41 [13922417.001]
  • [Cites] Eur J Cancer. 2004 Dec;40(18):2717-25 [15571953.001]
  • [Cites] FASEB J. 2005 Jan;19(1):115-7 [15629897.001]
  • [Cites] Cell Tissue Res. 2005 Feb;319(2):341-7 [15558322.001]
  • [Cites] Bioessays. 2005 Feb;27(2):153-63 [15666353.001]
  • [Cites] J Exp Med. 2005 Feb 7;201(3):419-30 [15699074.001]
  • [Cites] J Cell Biol. 2005 Feb 28;168(5):705-11 [15738264.001]
  • (PMID = 19029943.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA058541
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / E4 protein, Adenovirus 9; 0 / Gene Products, tax; 0 / Membrane Proteins; 0 / Oncogene Proteins, Viral; 0 / tax protein, Human T-lymphotrophic virus 1
  • [Number-of-references] 233
  • [Other-IDs] NLM/ NIHMS411909; NLM/ PMC3501650
  •  go-up   go-down


51. de Oliveira FM, Tone LG, Simões BP, Rego EM, Marinato AF, Jácomo RH, Falcão RP: Translocations t(X;14)(q28;q11) and t(Y;14)(q12;q11) in T-cell prolymphocytic leukemia. Int J Lab Hematol; 2009 Aug;31(4):453-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocations t(X;14)(q28;q11) and t(Y;14)(q12;q11) in T-cell prolymphocytic leukemia.
  • We report a case of T-cell prolymphocytic leukemia (T-PLL) in a 41-year-old male.
  • Classical cytogenetic, spectral karyotyping (SKY) and fluorescence in situ hybridization (FISH) studies of a blood sample obtained at diagnosis revealed the co-existence of t(X;14)(q28;q11), t(Y;14)(q12;q11) and a ring chromosome derived from i(8)(q10).
  • Immunophenotypic studies revealed involvement of T-cell lineage, with proliferation of CD4(-) CD8+.
  • Chromosomal instability associated with the disease progression may have allowed the emergence of cell clones with translocations involving the sex chromosomes and the ring chromosome observed.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, X / genetics. Chromosomes, Human, Y / genetics. Leukemia, Prolymphocytic, T-Cell / genetics. Ring Chromosomes. Translocation, Genetic
  • [MeSH-minor] Adult. Chromosomal Instability / genetics. Humans. Male. Spectral Karyotyping

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294235.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Castillo JJ, Morales D, Quinones P, Cotrina E, Desposorio C, Beltran B: Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma; 2010 Oct;51(10):1822-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified.
  • Peripheral T-cell lymphoma, unspecified (PTCLU) is the most common T-cell lymphoma variant.
  • The molecular heterogeneity of PTCLU is reflected by a diverse clinical course.
  • Sixty-nine cases with a pathological diagnosis of PTCLU were included in our analysis.
  • Lymphopenia was seen in 38% of the patients and was statistically associated with a worse response to chemotherapy.
  • In univariate analysis, lymphopenia, IPI score>2, and Prognostic Index for PTCLU (PIT) score>2 were associated with a worse overall survival.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology. Lymphopenia / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lymphocyte Count. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Oct;51(10):1773-4 [20849382.001]
  • (PMID = 20849388.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


53. Masuda M, Maruyama T, Ohta T, Ito A, Hayashi T, Tsukasaki K, Kamihira S, Yamaoka S, Hoshino H, Yoshida T, Watanabe T, Stanbridge EJ, Murakami Y: CADM1 interacts with Tiam1 and promotes invasive phenotype of human T-cell leukemia virus type I-transformed cells and adult T-cell leukemia cells. J Biol Chem; 2010 May 14;285(20):15511-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CADM1 interacts with Tiam1 and promotes invasive phenotype of human T-cell leukemia virus type I-transformed cells and adult T-cell leukemia cells.
  • CADM1 encodes a multifunctional immunoglobulin-like cell adhesion molecule whose cytoplasmic domain contains a type II PSD95/Dlg/ZO-1 (PDZ)-binding motif (BM) for associating with other intracellular proteins.
  • Although CADM1 lacks expression in T lymphocytes of healthy individuals, it is overexpressed in adult T-cell leukemia-lymphoma (ATL) cells.
  • It has been suggested that the expression of CADM1 protein promotes infiltration of leukemic cells into various organs and tissues, which is one of the frequent clinical manifestations of ATL.
  • Amino acid sequence alignment revealed that Tiam1 (T-lymphoma invasion and metastasis 1), a Rac-specific guanine nucleotide exchange factor, has a type II PDZ domain similar to those of membrane-associated guanylate kinase homologs (MAGUKs) that are known to bind to the PDZ-BM of CADM1.
  • In this study, we demonstrated that the cytoplasmic domain of CADM1 directly interacted with the PDZ domain of Tiam1 and induced formation of lamellipodia through Rac activation in HTLV-I-transformed cell lines as well as ATL cell lines.
  • Our results indicate that Tiam1 integrates signals from CADM1 to regulate the actin cytoskeleton through Rac activation, which may lead to tissue infiltration of leukemic cells in ATL patients.
  • [MeSH-major] Guanine Nucleotide Exchange Factors / metabolism. Human T-lymphotropic virus 1 / pathogenicity. Immunoglobulins / metabolism. Leukemia, T-Cell / pathology. Membrane Proteins / metabolism. Neoplasm Invasiveness. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Amino Acid Sequence. Base Sequence. Cell Adhesion Molecules. Cell Line, Tumor. Humans. Immunohistochemistry. Microscopy, Confocal. Molecular Sequence Data. Protein Binding. RNA Interference. RNA, Small Interfering. Sequence Homology, Amino Acid

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1999 Dec 1;62(2):139-46 [10610705.001]
  • [Cites] Retrovirology. 2006;3:71 [17042961.001]
  • [Cites] Nat Genet. 2001 Apr;27(4):427-30 [11279526.001]
  • [Cites] Annu Rev Neurosci. 2001;24:1-29 [11283303.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Mol Reprod Dev. 2001 Oct;60(2):158-64 [11553913.001]
  • [Cites] Neuroreport. 2001 Oct 29;12(15):3217-21 [11711859.001]
  • [Cites] Nature. 2002 Jun 20;417(6891):867-71 [12075356.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):31014-9 [12050160.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1525-31 [12202822.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5129-33 [12234973.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2601-8 [12456501.001]
  • [Cites] Biol Reprod. 2003 May;68(5):1755-63 [12606335.001]
  • [Cites] FEBS Lett. 2003 Jul 3;546(1):11-6 [12829230.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] Lab Invest. 2003 Aug;83(8):1175-83 [12920246.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35421-7 [12826663.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6160-5 [13679854.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):583-9 [14519393.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7979-85 [14633730.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):495-508 [14530271.001]
  • [Cites] Cell. 2004 Jan 23;116(2):167-79 [14744429.001]
  • [Cites] Trends Cell Biol. 2007 Jan;17(1):36-43 [17126549.001]
  • [Cites] Hepatology. 2007 Mar;45(3):684-94 [17326163.001]
  • [Cites] J Cell Biol. 2007 Mar 12;176(6):863-75 [17353362.001]
  • [Cites] J Biol Chem. 2007 May 4;282(18):13864-74 [17339315.001]
  • [Cites] Rev Med Virol. 2007 Sep-Oct;17(5):301-11 [17621367.001]
  • [Cites] J Neurosci. 2007 Nov 14;27(46):12516-30 [18003830.001]
  • [Cites] Retrovirology. 2008;5:76 [18702816.001]
  • [Cites] J Virol. 2008 Dec;82(23):11958-63 [18922876.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(1):21-32 [14999151.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Oct;80(19):6061-5 [6193528.001]
  • [Cites] Int J Cancer. 1990 Feb 15;45(2):237-43 [2303290.001]
  • [Cites] Cell. 1994 May 20;77(4):537-49 [7999144.001]
  • [Cites] Nature. 1995 May 25;375(6529):338-40 [7753201.001]
  • [Cites] Science. 1997 Jan 3;275(5296):73-7 [8974395.001]
  • [Cites] J Cell Biol. 1997 Apr 21;137(2):387-98 [9128250.001]
  • [Cites] Science. 1997 Nov 21;278(5342):1464-6 [9367959.001]
  • [Cites] EMBO J. 1998 Jul 15;17(14):4066-74 [9670021.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):501-11 [9927410.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):185-90 [15621800.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1204-13 [15471956.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):6934-42 [15905536.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):21955-64 [15781451.001]
  • [Cites] Retrovirology. 2005;2:27 [15854229.001]
  • [Cites] Blood. 2005 Aug 1;106(3):779-86 [15811952.001]
  • [Cites] Int Immunol. 2005 Sep;17(9):1227-37 [16091383.001]
  • [Cites] Cancer Sci. 2005 Sep;96(9):543-52 [16128739.001]
  • [Cites] J Biol Chem. 2005 Dec 23;280(51):42164-71 [16223734.001]
  • [Cites] Trends Cell Biol. 2006 Oct;16(10):522-9 [16949823.001]
  • [Cites] Cancer Sci. 2006 Nov;97(11):1139-46 [16952304.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):369-76 [11054665.001]
  • (PMID = 20215110.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CADM1 protein, human; 0 / Cell Adhesion Molecules; 0 / Guanine Nucleotide Exchange Factors; 0 / Immunoglobulins; 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / TIAM1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2865322
  •  go-up   go-down


54. Sugita S, Takase H, Yoshida T, Sugamoto Y, Watanabe T, Mochizuki M: Intraocular soluble IL-2 receptor alpha in a patient with adult T cell leukaemia with intraocular invasion. Br J Ophthalmol; 2006 Sep;90(9):1204-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraocular soluble IL-2 receptor alpha in a patient with adult T cell leukaemia with intraocular invasion.
  • [MeSH-major] Biomarkers, Tumor / analysis. Eye / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemic Infiltration / immunology. Receptors, Interleukin-2 / analysis

  • MedlinePlus Health Information. consumer health - Eye Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ophthalmol. 2002 Oct;134(4):616-8 [12383828.001]
  • [Cites] J Lab Clin Med. 1989 Oct;114(4):407-10 [2794753.001]
  • [Cites] J Clin Invest. 1995 Feb;95(2):852-8 [7860769.001]
  • [Cites] Arch Ophthalmol. 1994 Jul;112(7):954-9 [8031276.001]
  • [Cites] Rinsho Ketsueki. 1992 Apr;33(4):537-41 [1318431.001]
  • (PMID = 16929066.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Receptors, Interleukin-2
  • [Other-IDs] NLM/ PMC1857395
  •  go-up   go-down


55. Gómez Pescie M, Denninghoff V, García A, Rescia C, Avagnina A, Elsner B: [Mantle cell lymphoma vs. atypical chronic lymphocytic leukemia. Use of immunohistochemistry, flow cytometry and molecular biology for their adequate typing]. Medicina (B Aires); 2005;65(5):419-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mantle cell lymphoma vs. atypical chronic lymphocytic leukemia. Use of immunohistochemistry, flow cytometry and molecular biology for their adequate typing].
  • [Transliterated title] Linfoma del manto vs. leucemia linfatica crónica atipica. Utilización de inmunohistoquímica, citometría de flujo y biología molecular para su correcta tipificación.
  • The differential diagnosis of certain B CD5+ lymphoproliferative processes, such as mantle cell lymphoma (MCL) and atypical chronic lymphocytic leukemia (ACLL), is difficult.
  • Twelve cases were diagnosed as MCL, with positive cD1 in 5 (5/9), five as ACLL and three as B lymphoproliferative process.
  • Molecular biology evidenced translocation in 4/5 MCL positive for cD1 with IHC.
  • [MeSH-major] Cyclin D1 / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Mantle-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD5 / metabolism. Bone Marrow / pathology. Diagnosis, Differential. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Spleen / pathology


56. Larson RA: Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program; 2007;:453-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiology and management of therapy-related myeloid leukemia.
  • The diagnosis of therapy-related myeloid leukemia (t-MDS/t-AML) identifies a group of high-risk patients with multiple and varied poor prognostic features.
  • Their outcomes have historically been poor compared with those of people who develop acute myeloid leukemia (AML) de novo.
  • The question arises whether a diagnosis of t-AML per se indicates a poor prognosis, or whether their bad outcomes result from other clinical and biologic characteristics.
  • Because of lingering damage from prior cytotoxic therapy and, in some cases, the persistence of their primary disorder, patients with t-AML are often poor candidates for intensive AML therapy.
  • The spectrum of cytogenetic abnormalities in t-AML is similar to de novo AML, but the frequency of unfavorable cytogenetics, such as a complex karyotype or deletion or loss of chromosomes 5 and/or 7, is higher in t-AML.
  • Patients with t-AML should be enrolled on front-line chemotherapy trials, appropriate for de novo AML patients with similar disease characteristics.
  • Allogeneic hematopoietic cell transplantation can cure some patients with t-AML.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024664.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA14599; United States / NCI NIH HHS / CA / CA40046
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 29
  •  go-up   go-down


57. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Müller MC, Beneke H, Müller L, Del Valle F, Aulitzky WE, Wittkowsky G, Schmitz N, Schulte C, Müller-Hermelink K, Hodges E, Whittaker SJ, Diecker F, Döhner H, Schuld P, Hehlmann R, Hochhaus A, Cross NC, Reiter A: Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia; 2007 Jun;21(6):1183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
  • The FIP1L1-PDGFRA fusion gene has been described in patients with eosinophilia-associated myeloproliferative disorders (Eos-MPD).
  • Here, we report on seven FIP1L1-PDGFRA-positive patients who presented with acute myeloid leukemia (AML, n=5) or lymphoblastic T-cell non-Hodgkin-lymphoma (n=2) in conjunction with AML or Eos-MPD.
  • Patients were treated with imatinib (100 mg, n=5; 400 mg, n=2) either as monotherapy (n=2), as maintenance treatment after intensive chemotherapy (n=3) or in overt relapse 43 and 72 months, respectively, after primary diagnosis and treatment of FIP1L1-PDGFRA-positive disease (n=2).
  • All patients are alive, disease-free and in complete hematologic and complete molecular remission after a median time of 20 months (range, 9-36) on imatinib.
  • We conclude that all eosinophilia-associated hematological malignancies should be screened for the presence of the FIP1L1-PDGFRA fusion gene as they are excellent candidates for treatment with tyrosine kinase inhibitors even if they present with an aggressive phenotype such as AML.
  • [MeSH-major] Eosinophilia / drug therapy. Leukemia, Myeloid / drug therapy. Oncogene Proteins, Fusion / analysis. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage. Receptor, Platelet-Derived Growth Factor alpha. mRNA Cleavage and Polyadenylation Factors
  • [MeSH-minor] Acute Disease. Adult. Aged. Benzamides. Disease-Free Survival. Humans. Imatinib Mesylate. Male. Middle Aged. Myeloproliferative Disorders / drug therapy. Protein-Tyrosine Kinases / antagonists & inhibitors. Remission Induction / methods


58. Schlenk RF, Pasquini MC, Pérez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Büchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Döhner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A, CIBMTR Acute Leukemia Working Committee: HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant; 2008 Feb;14(2):187-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.
  • We studied the role of HLA-matched sibling hematopoietic cell transplantation (HCT) in treating t(8;21) acute myelogenous leukemia (AML) in first remission.
  • Transplants were associated with higher treatment-related mortality (TRM; relative risk [RR] 6.76, 95% confidence interval [CI] 2.95-15.45, P < .001), lower relapse (RR 0.47, 95% CI 0.25-0.85, P = .01), and similar relapse-free survival (P = .2).
  • In both cohorts, white blood cell count (WBC) at diagnosis >25 x 10(9)/L was associated with a higher relapse risk (RR = 2.09, P = .03), lower relapse-free (RR = 1.9, P = .008), and OS (RR = 1.91, P = .01).

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3767-75 [10577848.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5074-87 [16051954.001]
  • [Cites] N Engl J Med. 2001 Jan 18;344(3):175-81 [11172139.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):300-7 [11167822.001]
  • [Cites] Leuk Lymphoma. 2000 Dec;40(1-2):67-77 [11426630.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1309-10 [11965278.001]
  • [Cites] Blood. 2002 May 15;99(10):3517-23 [11986202.001]
  • [Cites] Blood. 2002 Aug 1;100(3):761-7 [12130483.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):385-400 [12139722.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1525-31 [12176866.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Blood. 2003 Jul 15;102(2):462-9 [12649129.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1521-8 [12886238.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4496-504 [14673036.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Ann Hematol. 2004 Jun;83(6):336-44 [15034758.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3741-50 [15289486.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1081-6 [2754449.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1825-31 [1391946.001]
  • [Cites] N Engl J Med. 1995 Jan 26;332(4):217-23 [7808487.001]
  • [Cites] Leukemia. 1996 Aug;10(8):1288-95 [8709633.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3904-11 [16921041.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):165-73 [16939487.001]
  • [Cites] Leukemia. 1996 Nov;10(11):1687-91 [8892667.001]
  • [Cites] Eur J Haematol. 1997 Jul;59(1):47-52 [9260580.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2978-86 [9376578.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9 [15650049.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • (PMID = 18215779.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518-10; United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-09; United States / NCI NIH HHS / CA / U24-CA76518; United States / NCI NIH HHS / CA / U24 CA076518-08; United States / NCI NIH HHS / CA / CA076518-08
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS39951; NLM/ PMC2531160
  •  go-up   go-down


59. Zhang J, Yamada O, Matsushita Y, Chagan-Yasutan H, Hattori T: Transactivation of human osteopontin promoter by human T-cell leukemia virus type 1-encoded Tax protein. Leuk Res; 2010 Jun;34(6):763-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transactivation of human osteopontin promoter by human T-cell leukemia virus type 1-encoded Tax protein.
  • We report here that OPN gene is transactivated by Tax protein of human T-cell leukemia virus type 1 (HTLV-1).
  • This study suggests that OPN is one of the downstream mediators of aberrantly activated PI3K/AKT signaling by Tax, which may partially contribute to HTLV-1-associated leukemogenesis.
  • [MeSH-minor] Base Sequence. Binding Sites. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Cell Transformation, Viral / genetics. Gene Expression Regulation, Neoplastic. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / physiology. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Phosphatidylinositol 3-Kinases / metabolism. Phosphatidylinositol 3-Kinases / physiology. Promoter Regions, Genetic / physiology. Proto-Oncogene Proteins c-akt / metabolism. Proto-Oncogene Proteins c-akt / physiology. Signal Transduction / genetics. Transcription Factor AP-1 / metabolism

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19767100.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Transcription Factor AP-1; 0 / tax protein, Human T-lymphotrophic virus 1; 106441-73-0 / Osteopontin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


60. Peloponese JM Jr, Yeung ML, Jeang KT: Modulation of nuclear factor-ϰB by human T cell leukemia virus type 1 tax protein : Implications for oncogenesis and inflammation. Immunol Res; 2006 Jan;34(1):1-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of nuclear factor-ϰB by human T cell leukemia virus type 1 tax protein : Implications for oncogenesis and inflammation.
  • Human T cell leukemia virus type 1 (HTLV-1) is the causative agent of a fatal malignancy known as adult T cell leukemia (ATL) and an inflammatory disease named tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM).
  • HTLV-1 encodes an oncoprotein, Tax, which plays a significant role in the initiation of cellular transformation and the elicitation of the host's inflammatory responses.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 1999 Nov;11(5):547-54 [10591180.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5952-64 [16155602.001]
  • [Cites] Science. 1997 Oct 31;278(5339):860-6 [9346484.001]
  • [Cites] Curr Biol. 1999 Jun 3;9(11):601-4 [10359702.001]
  • [Cites] J Virol. 1992 Dec;66(12):7183-92 [1433511.001]
  • [Cites] Nature. 1998 Jan 22;391(6665):410-3 [9450761.001]
  • [Cites] Science. 1997 Oct 31;278(5339):866-9 [9346485.001]
  • [Cites] Annu Rev Immunol. 2000;18:621-63 [10837071.001]
  • [Cites] Annu Rev Immunol. 1994;12:141-79 [8011280.001]
  • [Cites] Retrovirology. 2005 Mar 02;2:16 [15743528.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30099-105 [15140882.001]
  • [Cites] J Biol Chem. 2000 Nov 3;275(44):34060-7 [10906125.001]
  • [Cites] Cell. 1997 Jul 25;90(2):373-83 [9244310.001]
  • [Cites] Mol Cell. 2001 Feb;7(2):401-9 [11239468.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5926-30 [16155599.001]
  • [Cites] Immunity. 2002 Oct;17 (4):525-35 [12387745.001]
  • [Cites] Genes Dev. 2001 Sep 15;15(18):2321-42 [11562344.001]
  • [Cites] Biochim Biophys Acta. 1992 Dec 16;1114(2-3):223-33 [1333808.001]
  • [Cites] J Exp Med. 1997 Oct 6;186(7):999-1014 [9314550.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6938-47 [10602468.001]
  • [Cites] Retrovirology. 2005 Mar 02;2:17 [15743526.001]
  • [Cites] J Virol. 1999 Jun;73(6):4856-65 [10233947.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18137-45 [14963024.001]
  • [Cites] Retrovirology. 2005 Apr 26;2:27 [15854229.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5965-75 [16155603.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6026-34 [16155609.001]
  • [Cites] Annu Rev Immunol. 1998;16:225-60 [9597130.001]
  • [Cites] Cell. 1992 Mar 20;68(6):1121-33 [1547506.001]
  • [Cites] EMBO J. 1996 Feb 15;15(4):873-87 [8631308.001]
  • [Cites] Annu Rev Cell Biol. 1994;10:405-55 [7888182.001]
  • [Cites] Genes Dev. 2000 Jul 15;14 (14 ):1729-33 [10898787.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5 [11572954.001]
  • [Cites] Oncogene. 2003 Dec 4;22(55):8912-23 [14654787.001]
  • [Cites] Mol Cell Biol. 1994 Feb;14(2):1374-82 [8289813.001]
  • [Cites] Oncogene. 1994 Jul;9(7):1931-7 [8208540.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36005-12 [12840022.001]
  • [Cites] J Exp Med. 2003 Sep 1;198(5):771-81 [12939342.001]
  • [Cites] Science. 1999 May 21;284(5418):1313-8 [10334979.001]
  • [Cites] J Biol Chem. 1999 May 28;274(22):15297-300 [10336413.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6853-66 [10602461.001]
  • [Cites] Oncogene. 2000 Oct 26;19(45):5198-203 [11064457.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6948-58 [10602469.001]
  • [Cites] Nature. 2001 May 31;411(6837):603-6 [11385577.001]
  • [Cites] Retrovirology. 2005 Feb 01;2:4 [15686595.001]
  • [Cites] Acta Paediatr Jpn. 1992 Jun;34(3):358-64 [1509882.001]
  • [Cites] EMBO J. 2001 Dec 3;20(23 ):6805-15 [11726516.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] J Exp Med. 1998 Jan 19;187(2):147-59 [9432973.001]
  • [Cites] Oncogene. 2000 Mar 9;19(11):1448-56 [10723136.001]
  • [Cites] Science. 2001 Mar 16;291(5511):2162-5 [11251123.001]
  • [Cites] EMBO J. 2002 Oct 15;21(20):5375-85 [12374738.001]
  • [Cites] Mol Cell Biol. 1993 Oct;13(10):6137-46 [8413215.001]
  • [Cites] Cell. 1996 Oct 4;87(1):13-20 [8858144.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6719-28 [16007163.001]
  • [Cites] Retrovirology. 2005 Dec 09;2:75 [16336683.001]
  • [Cites] Oncogene. 1993 Oct;8(10):2839-45 [8378093.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2994-9 [10077625.001]
  • [Cites] Oncogene. 1994 Aug;9(8):2335-44 [8036016.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2493-503 [11971184.001]
  • [Cites] Cell. 1997 Oct 17;91(2):243-52 [9346241.001]
  • [Cites] Retrovirology. 2005 May 06;2:29 [15876358.001]
  • [Cites] Nature. 1997 Aug 7;388(6642):548-54 [9252186.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6888-95 [10602464.001]
  • [Cites] Immunol Today. 1998 Feb;19(2):80-8 [9509763.001]
  • [Cites] Oncogene. 2003 Jul 31;22(31):4868-74 [12894228.001]
  • [Cites] J Exp Med. 1988 Mar 1;167(3):1259-64 [2832508.001]
  • [Cites] Science. 1999 Sep 24;285(5436):2122-5 [10497129.001]
  • [Cites] Annu Rev Immunol. 1997;15:15-37 [9143680.001]
  • [Cites] J Biol Chem. 2004 Oct 22;279(43):44563-72 [15310758.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Nov 27;181(1):80-6 [1958222.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Jun;4(3):369-76 [15161436.001]
  • [Cites] EMBO J. 2004 Oct 27;23 (21):4202-10 [15470505.001]
  • [Cites] Oncogene. 1994 Mar;9(3):841-52 [8108127.001]
  • [Cites] Cell. 1998 Jun 26;93(7):1231-40 [9657155.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6005-15 [16155607.001]
  • [Cites] J Virol. 2005 Jul;79(14 ):9346-50 [15994832.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):22911-4 [10438454.001]
  • [Cites] Science. 1999 Apr 9;284(5412):316-20 [10195896.001]
  • [Cites] J Biol Chem. 2005 Dec 9;280(49):40965-73 [16207722.001]
  • [Cites] Semin Cancer Biol. 1997 Apr;8(2):75-82 [9299585.001]
  • [Cites] Genes Dev. 1990 Nov;4(11):1875-85 [2276622.001]
  • [Cites] EMBO J. 1997 Dec 1;16(23):7078-90 [9384586.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5931-7 [16155600.001]
  • [Cites] J Cell Physiol. 2002 Feb;190(2):133-59 [11807819.001]
  • [Cites] J Cell Mol Med. 2005 Jan-Mar;9(1):59-71 [15784165.001]
  • [Cites] Cell Signal. 2002 May;14(5):381-95 [11882383.001]
  • [Cites] J Biol Chem. 2005 Jan 7;280(1):18-27 [15485830.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18827-35 [10373501.001]
  • [Cites] J Theor Biol. 2000 Nov 7;207(1):65-79 [11027480.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Jun-Sep;12 (2-3):207-17 [11325603.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35713-22 [16105841.001]
  • [Cites] Genes Dev. 1995 Nov 15;9(22):2736-46 [7590249.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17402-5 [10364167.001]
  • [Cites] Nature. 1995 Jan 26;373(6512):303-10 [7530332.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4484-96 [11494144.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6035-46 [16155610.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3065-73 [8874205.001]
  • [Cites] J Exp Med. 1998 Jan 19;187(2):185-96 [9432976.001]
  • (PMID = 27519575.001).
  • [ISSN] 0257-277X
  • [Journal-full-title] Immunologic research
  • [ISO-abbreviation] Immunol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Adult T cell leukemia (ATL) / HTLV-1 Tax / Human T cell leukemia virus (HTLV-1) / IKK / Inflammation / NF-ϰB / NIK
  •  go-up   go-down


61. Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T: Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood; 2009 Apr 23;113(17):3911-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival.
  • A population-based cohort was used to determine the incidence and risk factors associated with development of venous thromboembolism (VTE) among Californians diagnosed with acute leukemia between 1993 to 1999.
  • Among 5394 cases with acute myelogenous leukemia (AML), the 2-year cumulative incidence of VTE was 281 (5.2%).
  • Sixty-four percent of the VTE events occurred within 3 months of AML diagnosis.
  • A diagnosis of VTE was not associated with reduced survival in AML patients.
  • Among 2482 cases with acute lymphoblastic leukemia (ALL), the 2-year incidence of VTE in ALL was 4.5%.
  • In the patients with ALL, development of VTE was associated with a 40% increase in the risk of dying within 1 year.
  • The incidence of VTE in acute leukemia is appreciable, and is comparable with the incidence in many solid tumors.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 2006 Jan;119(1):60-8 [16431186.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):484-90 [16421425.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1112-8 [16505431.001]
  • [Cites] Hematol Oncol. 2006 Sep;24(3):126-33 [16783843.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2216-22 [16804111.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):70-6 [17194906.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):601-8 [17432710.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):784-90 [17408726.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2339-46 [17918266.001]
  • [Cites] Blood. 2008 May 15;111(10):4902-7 [18216292.001]
  • [Cites] Semin Thromb Hemost. 2006 Apr;32 Suppl 1:61-8 [16673267.001]
  • [Cites] N Engl J Med. 2000 Dec 21;343(25):1846-50 [11117976.001]
  • [Cites] Med Care. 2001 Jul;39(7):727-39 [11458137.001]
  • [Cites] Blood Coagul Fibrinolysis. 2001 Jul;12(5):367-70 [11505079.001]
  • [Cites] Semin Thromb Hemost. 2001 Dec;27(6):593-604 [11740683.001]
  • [Cites] Thromb Res. 2003;111(3):125-31 [14678808.001]
  • [Cites] Thromb Res. 2003;111(4-5):199-212 [14693164.001]
  • [Cites] Thromb Res. 2003;111(6):321-7 [14698648.001]
  • [Cites] Am J Med. 2004 Jul 1;117(1):19-25 [15210384.001]
  • [Cites] Tumori. 2004 Jul-Aug;90(4):390-3 [15510981.001]
  • [Cites] Leuk Lymphoma. 1996 Feb;20(5-6):435-9 [8833399.001]
  • [Cites] Med Care. 1998 Jan;36(1):8-27 [9431328.001]
  • [Cites] Ann Intern Med. 1998 May 1;128(9):737-40 [9556467.001]
  • [Cites] Semin Thromb Hemost. 1999;25(2):173-82 [10357085.001]
  • [Cites] Medicine (Baltimore). 1999 Sep;78(5):285-91 [10499070.001]
  • [Cites] Thromb Res. 2005;115(1-2):59-64 [15567454.001]
  • [Cites] JAMA. 2005 Feb 9;293(6):715-22 [15701913.001]
  • [Cites] Dis Mon. 2005 Feb-Mar;51(2-3):150-7 [15900267.001]
  • [Cites] J Thromb Haemost. 2005 Sep;3(9):1985-92 [16102104.001]
  • [Cites] Arch Intern Med. 2006 Feb 27;166(4):458-64 [16505267.001]
  • (PMID = 19088376.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA099527; United States / NCRR NIH HHS / RR / UL1 RR024146; United States / NCI NIH HHS / CA / 1-RO3-CA99527-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2673120
  •  go-up   go-down


62. Fahim S, Prokopetz R, Jackson R, Faught C, McCarthy AE, Andonov A, Coulthart M, Daw Z, Olberg B, Giulivi A, Padmore R: Human T-cell lymphotropic virus type 1-associated adult T-cell leukemia/lymphoma in the Inuit people of Nunavut. CMAJ; 2006 Sep 12;175(6):579
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T-cell lymphotropic virus type 1-associated adult T-cell leukemia/lymphoma in the Inuit people of Nunavut.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / ethnology
  • [MeSH-minor] Adult. Aged. Fatal Outcome. Female. Humans. Indians, North American. Lymphocytosis / blood. Medical History Taking. Middle Aged. Physical Examination. Practice Guidelines as Topic

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tissue Antigens. 1998 Nov;52(5):444-51 [9864034.001]
  • [Cites] CMAJ. 2006 Jan 17;174(2):150-1 [16415454.001]
  • [Cites] Am J Hematol. 2005 Mar;78(3):232-9 [15726602.001]
  • (PMID = 16966657.001).
  • [ISSN] 1488-2329
  • [Journal-full-title] CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • [ISO-abbreviation] CMAJ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC1559419
  •  go-up   go-down


63. Oshikawa G, Kurosu T, Arai A, Murakami N, Miura O: Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation. Cancer Genet Cytogenet; 2010 May;199(1):56-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
  • Chronic myeloid leukemia (CML) with the e19a2 transcript coding for p230 is typically associated with a benign clinical course unless accompanied at presentation with additional chromosomal abnormalities.
  • We report here a case of CML with e19a2 who did not show additional chromosomal abnormalities at diagnosis, but progressed to the fatal advanced stage in approximately 2 years.
  • The patient died of disease progression in 2 months.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Fusion Proteins, bcr-abl / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Philadelphia Chromosome. Piperazines / therapeutic use. Polyploidy. Pyrimidines / therapeutic use. RNA, Neoplasm / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Base Sequence. Benzamides. Bone Marrow / pathology. Clone Cells. DNA Mutational Analysis. Female. Gene Expression Regulation, Leukemic. Humans. Imatinib Mesylate. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Molecular Sequence Data. RNA, Messenger / genetics. RNA, Messenger / metabolism. Time Factors

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Tetraploidy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20417871.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / abl-bcr fusion protein, human; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


64. Mesnard JM, Barbeau B, Devaux C: HBZ, a new important player in the mystery of adult T-cell leukemia. Blood; 2006 Dec 15;108(13):3979-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HBZ, a new important player in the mystery of adult T-cell leukemia.
  • Adult T-cell leukemia (ATL) was first described in 1977.
  • A link between ATL and human T-cell leukemia virus type 1 (HTLV-1) was clearly established in the early 1980s.
  • Over the years, many aspects of HTLV-1-induced cellular dysfunctions have been clarified.
  • However, the detailed mechanism behind ATL occurrence remains unsolved.
  • Presently, we are still unable to explain the absence of viral Tax protein (thought to play a central role in T-cell transformation) in more than 50% of ATL cells.
  • A novel HTLV-1 HBZ protein, encoded on the negative strand, was characterized by our group and is currently the subject of intensive research efforts to determine its function in viral replication and/or pathophysiology.
  • Recently, 4 studies reported on the existence of different HBZ isoforms and have investigated on their function in both ATL cells or animal models.
  • [MeSH-major] Basic-Leucine Zipper Transcription Factors / genetics. Cell Transformation, Viral / genetics. Human T-lymphotropic virus 1 / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Viral Proteins / genetics. Virus Replication / genetics
  • [MeSH-minor] Animals. Cell Proliferation. Disease Models, Animal. Gene Products, tax / deficiency. Gene Products, tax / immunology. Humans. Protein Isoforms / genetics. Protein Isoforms / immunology. RNA, Messenger / genetics. RNA, Messenger / immunology. RNA, Viral / genetics. RNA, Viral / immunology. T-Lymphocytes / immunology. T-Lymphocytes / pathology. T-Lymphocytes / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917009.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic-Leucine Zipper Transcription Factors; 0 / Gene Products, tax; 0 / HBZ protein, human T-cell leukemia virus type I; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / RNA, Viral; 0 / Viral Proteins
  • [Number-of-references] 102
  •  go-up   go-down


65. Ariumi Y, Trono D: Ataxia-telangiectasia-mutated (ATM) protein can enhance human immunodeficiency virus type 1 replication by stimulating Rev function. J Virol; 2006 Mar;80(5):2445-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ataxia-telangiectasia-mutated (ATM) protein can enhance human immunodeficiency virus type 1 replication by stimulating Rev function.
  • The ataxia-telangiectasia-mutated (ATM) kinase plays a central role in responses to various forms of DNA damage and has been suggested to facilitate human immunodeficiency virus type 1 (HIV-1) integration.
  • Notably, ATM overexpression did not stimulate the HIV-1 late gene expression within the context of Rev-independent constructs or the Rex-dependent production of capsid from human T-cell leukemia virus type 1 proviral constructs.
  • [MeSH-major] Cell Cycle Proteins / physiology. DNA-Binding Proteins / physiology. Gene Expression Regulation, Viral. Gene Products, rev / physiology. HIV-1 / physiology. Protein-Serine-Threonine Kinases / physiology. Tumor Suppressor Proteins / physiology. Virus Replication
  • [MeSH-minor] Ataxia Telangiectasia Mutated Proteins. Caffeine. Cell Line. Gene Silencing. Genes, Reporter. HIV Core Protein p24 / analysis. Humans. Luciferases / analysis. Luciferases / genetics. rev Gene Products, Human Immunodeficiency Virus

  • Genetic Alliance. consumer health - Ataxia.
  • Genetic Alliance. consumer health - Ataxia Telangiectasia.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CAFFEINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • eagle-i research resources. PMID 16474151 (Special Collections) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 1997 Oct 1;7(10):767-75 [9368759.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1051-60 [9323133.001]
  • [Cites] J Virol. 1998 Aug;72(8):6602-7 [9658105.001]
  • [Cites] Mol Cell. 1998 Apr;1(5):649-59 [9660949.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10146-51 [9707615.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1677-9 [9733515.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2261-71 [10327072.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4375-82 [10485486.001]
  • [Cites] Virology. 2004 Dec 20;330(2):471-80 [15567440.001]
  • [Cites] J Virol. 2005 Feb;79(3):1389-96 [15650165.001]
  • [Cites] J Virol. 2005 Feb;79(4):2058-65 [15681408.001]
  • [Cites] J Virol. 2005 Mar;79(5):2973-8 [15709017.001]
  • [Cites] Nat Cell Biol. 2005 May;7(5):493-500 [15834407.001]
  • [Cites] J Biol Chem. 1999 Nov 26;274(48):34277-82 [10567403.001]
  • [Cites] Nucleic Acids Res. 2000 Feb 15;28(4):901-10 [10648781.001]
  • [Cites] J Biol Chem. 2000 Apr 7;275(14):10342-8 [10744722.001]
  • [Cites] J Virol. 2000 May;74(10):4839-52 [10775623.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Sep 21;287(2):556-61 [11554765.001]
  • [Cites] Science. 2002 Apr 19;296(5567):550-3 [11910072.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):155-68 [12612651.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4778-83 [12679521.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):263-4 [12796781.001]
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):754-61 [12883554.001]
  • [Cites] Trends Biochem Sci. 2003 Aug;28(8):419-24 [12932730.001]
  • [Cites] Virology. 2003 Sep 15;314(1):460-7 [14517098.001]
  • [Cites] EMBO J. 2003 Dec 15;22(24):6610-20 [14657032.001]
  • [Cites] Science. 2004 Apr 2;304(5667):93-6 [15064416.001]
  • [Cites] EMBO J. 2004 Jul 7;23(13):2632-40 [15201866.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:3187-208 [15353349.001]
  • [Cites] Cell. 2004 Oct 29;119(3):381-92 [15507209.001]
  • [Cites] J Gen Virol. 1987 Feb;68 ( Pt 2):499-506 [3029287.001]
  • [Cites] EMBO J. 1990 Dec;9(12):4155-60 [2249669.001]
  • [Cites] J Mol Biol. 1994 Sep 2;241(5):651-62 [7520946.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1480-4 [7878004.001]
  • [Cites] J Virol. 1995 Apr;69(4):2024-30 [7884847.001]
  • [Cites] J Virol. 1995 Aug;69(8):5048-56 [7541845.001]
  • [Cites] Virology. 1996 Mar 1;217(1):293-300 [8599214.001]
  • [Cites] Leuk Res. 2005 Aug;29(8):933-42 [15978944.001]
  • [Cites] Science. 1996 Apr 12;272(5259):263-7 [8602510.001]
  • [Cites] Nat Biotechnol. 1997 Sep;15(9):871-5 [9306402.001]
  • [Cites] EMBO J. 1997 Dec 15;16(24):7500-10 [9405378.001]
  • (PMID = 16474151.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Gene Products, rev; 0 / HIV Core Protein p24; 0 / Tumor Suppressor Proteins; 0 / rev Gene Products, Human Immunodeficiency Virus; 3G6A5W338E / Caffeine; EC 1.13.12.- / Luciferases; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC1395391
  •  go-up   go-down


66. Yoshida M, Satou Y, Yasunaga J, Fujisawa J, Matsuoka M: Transcriptional control of spliced and unspliced human T-cell leukemia virus type 1 bZIP factor (HBZ) gene. J Virol; 2008 Oct;82(19):9359-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional control of spliced and unspliced human T-cell leukemia virus type 1 bZIP factor (HBZ) gene.
  • The human T-cell leukemia virus type 1 (HTLV-1) basic leucine zipper factor (HBZ) gene is encoded by the minus strand of the HTLV-1 provirus and transcribed from the 3' long terminal repeat (LTR).
  • We compared the functions of the proteins derived from the sHBZ and usHBZ transcripts. sHBZ showed a stronger suppression of Tax-mediated transcriptional activation through the 5' LTR than did usHBZ; the level of suppression correlated with the level of protein produced.
  • The expression of sHBZ had a growth-promoting function in a T-cell line, while usHBZ expression did not.
  • [MeSH-major] Basic-Leucine Zipper Transcription Factors / chemistry. Human T-lymphotropic virus 1 / genetics. Sp1 Transcription Factor / metabolism. Transcription, Genetic. Viral Proteins / genetics. Viral Proteins / physiology
  • [MeSH-minor] Alternative Splicing. Base Sequence. Cell Proliferation. Gene Expression Regulation, Viral. Gene Products, tax / metabolism. Humans. Molecular Sequence Data. Promoter Regions, Genetic. RNA, Viral / metabolism. Terminal Repeat Sequences

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):43620-7 [12937177.001]
  • [Cites] Proteomics. 2008 Feb;8(4):626-49 [18203265.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):559-67 [14991578.001]
  • [Cites] FEBS Lett. 2004 Mar 26;562(1-3):165-70 [15044019.001]
  • [Cites] Retrovirology. 2008;5:34 [18426605.001]
  • [Cites] J Virol. 2000 Sep;74(18):8277-85 [10954525.001]
  • [Cites] Oncogene. 2000 Aug 17;19(35):3988-98 [10962555.001]
  • [Cites] J Virol. 2000 Dec;74(23):11270-7 [11070026.001]
  • [Cites] Ann Hum Genet. 2000 Jan;64(Pt 1):83-6 [11246463.001]
  • [Cites] J Virol. 2001 Oct;75(20):9885-95 [11559821.001]
  • [Cites] J Virol. 2002 Dec;76(24):12813-22 [12438606.001]
  • [Cites] Science. 2003 Mar 14;299(5613):1713-6 [12589003.001]
  • [Cites] Annu Rev Biochem. 2003;72:449-79 [12651739.001]
  • [Cites] Cell. 1983 Nov;35(1):79-87 [6313230.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jun;84(11):3653-7 [3035544.001]
  • [Cites] Blood. 1987 Oct;70(4):1069-72 [3115332.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Sep 15;163(2):1006-13 [2476979.001]
  • [Cites] Genes Dev. 1990 Nov;4(11):1875-85 [2276622.001]
  • [Cites] J Virol. 1991 Aug;65(8):4525-8 [2072462.001]
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):5229-43 [1922043.001]
  • [Cites] New Biol. 1991 Sep;3(9):896-906 [1931834.001]
  • [Cites] J Biol Chem. 1992 Mar 25;267(9):6450 [1348249.001]
  • [Cites] J Virol. 1992 May;66(5):2928-33 [1373197.001]
  • [Cites] J Biol Chem. 1995 Aug 18;270(33):19487-94 [7642633.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1001-10 [15592508.001]
  • [Cites] Retrovirology. 2005;2:17 [15743526.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5938-51 [16155601.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):720-5 [16407133.001]
  • [Cites] J Virol. 2006 Mar;80(5):2495-505 [16474156.001]
  • [Cites] Gene. 2006 Feb 1;366(2):335-42 [16288839.001]
  • [Cites] Blood. 2006 May 15;107(10):3976-82 [16424388.001]
  • [Cites] Retrovirology. 2006;3:15 [16512901.001]
  • [Cites] J Virol. 2006 Aug;80(15):7427-38 [16840323.001]
  • [Cites] J Virol. 2007 Feb;81(4):1543-53 [17151132.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Nat Med. 2004 Feb;10(2):197-201 [14730358.001]
  • (PMID = 18653454.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic-Leucine Zipper Transcription Factors; 0 / Gene Products, tax; 0 / HBZ protein, human T-cell leukemia virus type I; 0 / RNA, Viral; 0 / Sp1 Transcription Factor; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2546946
  •  go-up   go-down


67. Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK, Radich JP, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey TR, Blume KG, Niederwieser D, Sandmaier BM: Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia; 2005 Jun;19(6):990-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.
  • A total of 24 patients (median age 58; range, 27-71 years) with chronic myeloid leukemia (CML) in first chronic (CP1) (n=14), second chronic (n=4), or accelerated phase (n=6) who were not candidates for conventional hematopoietic cell transplantation (HCT), received nonmyeloablative HCT from HLA-matched siblings a median of 28.5 (range, 11-271) months after diagnosis.
  • The proportions of grade II, III, and IV acute GVHD were 38, 4, and 8%, respectively.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800667.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA18029; United States / NCI NIH HHS / CA / CA78902; United States / NCI NIH HHS / CA / CA49605; United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / P01 CA078902
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


68. Kress AK, Schneider G, Pichler K, Kalmer M, Fleckenstein B, Grassmann R: Elevated cyclic AMP levels in T lymphocytes transformed by human T-cell lymphotropic virus type 1. J Virol; 2010 Sep;84(17):8732-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated cyclic AMP levels in T lymphocytes transformed by human T-cell lymphotropic virus type 1.
  • Human T-cell lymphotropic virus type 1 (HTLV-1), the cause of adult T-cell leukemia/lymphoma (ATLL), transforms CD4(+) T cells to permanent growth through its transactivator Tax.
  • HTLV-1-transformed cells share phenotypic properties with memory and regulatory T cells (T-reg).
  • This led us to determine cAMP levels in HTLV-1-transformed cells.
  • We found elevated cAMP concentrations as a consistent feature of all HTLV-1-transformed cell lines, including in vitro-HTLV-1-transformed, Tax-transformed, and patient-derived cells.
  • We found specific downregulation of the cAMP-degrading phosphodiesterase 3B (PDE3B) in HTLV-1-transformed cells, which was independent of Tax in transient expression experiments.
  • Overexpression of PDE3B led to a decrease of cAMP in HTLV-1-transformed cells.
  • Decreased expression of PDE3B was associated with inhibitory histone modifications at the PDE3B promoter and the PDE3B locus.
  • This shows that HTLV-1-transformed cells assume biological features of long-lived T-cell populations that potentially contribute to viral persistence.
  • [MeSH-major] Cell Transformation, Viral. Cyclic AMP / metabolism. HTLV-I Infections / metabolism. Human T-lymphotropic virus 1 / physiology. Leukemia-Lymphoma, Adult T-Cell / metabolism
  • [MeSH-minor] Cell Line, Transformed. Cells, Cultured. Cyclic Nucleotide Phosphodiesterases, Type 3 / genetics. Cyclic Nucleotide Phosphodiesterases, Type 3 / metabolism. Gene Products, tax / genetics. Gene Products, tax / metabolism. Humans. T-Lymphocytes / metabolism. T-Lymphocytes / virology

  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 1999 Sep 15;58(6):935-50 [10509746.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4458-62 [2873886.001]
  • [Cites] Cancer Sci. 2005 Aug;96(8):527-33 [16108835.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5938-51 [16155601.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6026-34 [16155609.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6035-46 [16155610.001]
  • [Cites] Int Immunol. 2006 Feb;18(2):269-77 [16361311.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4491-9 [16467195.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):488-520 [16968949.001]
  • [Cites] J Leukoc Biol. 2006 Oct;80(4):880-8 [16888088.001]
  • [Cites] Blood. 2006 Dec 15;108(13):3979-82 [16917009.001]
  • [Cites] J Virol. 2007 Mar;81(5):2524-30 [17151105.001]
  • [Cites] Nature. 2007 Feb 15;445(7129):771-5 [17220874.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):936-40 [17237761.001]
  • [Cites] Cell. 2007 Feb 23;128(4):669-81 [17320505.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] J Exp Med. 2007 Jun 11;204(6):1303-10 [17502663.001]
  • [Cites] J Biol Chem. 2007 Jun 29;282(26):18750-7 [17449469.001]
  • [Cites] J Immunol. 2008 Jan 15;180(2):931-9 [18178833.001]
  • [Cites] J Gen Physiol. 2008 Apr;131(4):293-305 [18378798.001]
  • [Cites] Blood. 2008 May 1;111(9):4741-51 [18276843.001]
  • [Cites] Blood. 2000 Jan 1;95(1):30-8 [10607681.001]
  • [Cites] FEBS Lett. 2001 Sep 7;505(1):136-40 [11557056.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):207-10 [11752295.001]
  • [Cites] Mol Cell Biol. 1985 Dec;5(12):3610-6 [3915782.001]
  • [Cites] Nature. 1988 Oct 20;335(6192):738-40 [3262832.001]
  • [Cites] J Virol. 1989 Apr;63(4):1604-11 [2538645.001]
  • [Cites] J Virol. 1989 Aug;63(8):3220-6 [2501514.001]
  • [Cites] J Virol. 1992 Jul;66(7):4570-5 [1351105.001]
  • [Cites] AIDS Res Hum Retroviruses. 1994 Oct;10(10):1259-68 [7531462.001]
  • [Cites] J Exp Med. 1995 Mar 1;181(3):985-92 [7532686.001]
  • [Cites] Clin Diagn Lab Immunol. 1995 May;2(3):349-55 [7545080.001]
  • [Cites] J Virol. 1998 Jan;72(1):633-40 [9420268.001]
  • [Cites] Retrovirology. 2008;5:76 [18702816.001]
  • [Cites] FEBS Lett. 2008 Oct 29;582(25-26):3614-8 [18835269.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3788-97 [18689544.001]
  • [Cites] Retrovirology. 2008;5:100 [19014482.001]
  • [Cites] Int J Cancer. 2009 Nov 15;125(10):2375-82 [19544530.001]
  • [Cites] Virus Genes. 2001 Dec;23(3):263-71 [11778694.001]
  • [Cites] Blood. 2002 May 1;99(9):3383-9 [11964307.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):710-8 [12209131.001]
  • [Cites] Virology. 2003 Dec 5;317(1):136-45 [14675632.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2039-46 [15026341.001]
  • [Cites] J Virol. 2004 Sep;78(18):9814-9 [15331715.001]
  • [Cites] J Immunol. 1971 Nov;107(5):1489-92 [4330163.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Apr;81(8):2534-7 [6326131.001]
  • [Cites] Gan. 1984 Sep;75(9):752-5 [6094296.001]
  • [Cites] J Gen Virol. 1985 Aug;66 ( Pt 8):1825-9 [2991447.001]
  • [Cites] Lancet. 1985 Aug 24;2(8452):407-10 [2863442.001]
  • [Cites] Lancet. 1986 May 3;1(8488):1031-2 [2871307.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 1;332(2):569-84 [15896717.001]
  • (PMID = 20573814.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE17718
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / tax protein, Human T-lymphotrophic virus 1; E0399OZS9N / Cyclic AMP; EC 3.1.4.17 / Cyclic Nucleotide Phosphodiesterases, Type 3; EC 3.1.4.17 / PDE3B protein, human
  • [Other-IDs] NLM/ PMC2918996
  •  go-up   go-down


69. Masutani H, Ueda S, Yodoi J: The thioredoxin system in retroviral infection and apoptosis. Cell Death Differ; 2005 Aug;12 Suppl 1:991-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human thioredoxin (TRX) was first identified in human T-cell leukemia virus type I (HTLV-I)-positive T-cell lines and is associated with the pathophysiology of retroviral infections.
  • Thioredoxin binding protein-2/vitamin D(3) upregulated protein 1 is a growth suppressor and its expression is suppressed in HTLV-I-transformed cells.
  • Studies of these molecules of the TRX system provide novel insights into the apoptosis associated with retroviral diseases.
  • [MeSH-minor] Animals. Glutathione / metabolism. HIV Infections / metabolism. HTLV-I Infections / metabolism. Humans. MAP Kinase Kinase Kinase 5 / metabolism. Membrane Proteins / metabolism. Peroxidases / metabolism. Peroxiredoxins

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15818395.001).
  • [ISSN] 1350-9047
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 52500-60-4 / Thioredoxins; EC 1.11.1.- / Peroxidases; EC 1.11.1.15 / Peroxiredoxins; EC 2.7.11.25 / MAP Kinase Kinase Kinase 5; GAN16C9B8O / Glutathione
  • [Number-of-references] 93
  •  go-up   go-down


70. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA: Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood; 2010 Jul 15;116(2):171-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
  • A pilot study was undertaken to assess the safety, activity, and immunogenicity of a polyvalent Wilms tumor gene 1 (WT1) peptide vaccine in patients with acute myeloid leukemia in complete remission but with molecular evidence of WT1 transcript.
  • Immune responses were evaluated by delayed-type hypersensitivity, CD4+ T-cell proliferation, CD3+ T-cell interferon-gamma release, and WT1 peptide tetramer staining.
  • Of the 9 evaluable patients, 7 completed 6 vaccinations and WT1-specific T-cell responses were noted in 7 of 8 patients.
  • Three patients who were HLA-A0201-positive showed significant increase in interferon-gamma-secreting cells and frequency of WT1 tetramer-positive CD8+ T cells.
  • With a mean follow-up of 30 plus or minus 8 months after diagnosis, median disease-free survival has not been reached.
  • Further studies are needed to establish the role of vaccination as viable postremission therapy for acute myeloid leukemia.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Leukemia, Myeloid, Acute / therapy. Oncogene Proteins / therapeutic use. Vaccination / methods. WT1 Proteins / therapeutic use
  • [MeSH-minor] Adult. Aged. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cytotoxicity, Immunologic. Disease-Free Survival. Female. HLA-A Antigens / genetics. HLA-A Antigens / immunology. HLA-A2 Antigen. Humans. Hypersensitivity, Delayed / immunology. Interferon-gamma / biosynthesis. Interferon-gamma / immunology. Kaplan-Meier Estimate. Male. Middle Aged. Pilot Projects. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Vaccines, Subunit / genetics. Vaccines, Subunit / immunology. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Immunization.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Dec 1;165(11):6047-55 [11086036.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2132-7 [12200377.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2892-900 [12829610.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1037-42 [14504104.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90 [15365188.001]
  • [Cites] Int J Cancer. 1998 Dec 9;78(6):740-9 [9833768.001]
  • [Cites] J Exp Med. 1998 Dec 21;188(12):2357-68 [9858522.001]
  • [Cites] Cancer Immunol Immunother. 2005 Aug;54(8):721-8 [16010587.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1318-23 [15920488.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1415-8 [15845894.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1324-32 [16219568.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8799-807 [16361568.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):34-42 [16397021.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jul;55(7):850-60 [16220325.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):231-6 [16611662.001]
  • [Cites] Leuk Res. 2006 Oct;30(10):1293-8 [16533527.001]
  • [Cites] Leukemia. 2007 May;21(5):868-76 [17361230.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4547-55 [17671141.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1781-7 [10688838.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1924-32 [17505014.001]
  • [Cites] Blood. 2008 Jan 1;111(1):236-42 [17875804.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1613-6 [18256684.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Nov;6(10):995-1002 [19176197.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6541-8 [19389880.001]
  • (PMID = 20400682.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00398138
  • [Grant] United States / NCI NIH HHS / CA / P01 CA023766; United States / PHS HHS / / P01 23766
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / Oncogene Proteins; 0 / Vaccines, Subunit; 0 / WT1 Proteins; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2910606
  •  go-up   go-down


71. Mukherjee S, Negi VS, Keitany G, Tanaka Y, Orth K: In vitro activation of the IkappaB kinase complex by human T-cell leukemia virus type-1 Tax. J Biol Chem; 2008 May 30;283(22):15127-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro activation of the IkappaB kinase complex by human T-cell leukemia virus type-1 Tax.
  • Human T-cell leukemia virus type-I expresses Tax, a 40-kDa oncoprotein that activates IkappaB kinase (IKK), resulting in constitutive activation of NFkappaB.

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Nov 3;275(44):34060-7 [10906125.001]
  • [Cites] Trends Biochem Sci. 2007 May;32(5):210-6 [17412595.001]
  • [Cites] Science. 2000 Nov 24;290(5496):1594-7 [11090361.001]
  • [Cites] Annu Rev Immunol. 2001;19:475-96 [11244044.001]
  • [Cites] J Biol Chem. 2003 Jan 17;278(3):1487-93 [12419799.001]
  • [Cites] Exp Biol Med (Maywood). 2003 Feb;228(2):111-33 [12563018.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):48903-6 [14514672.001]
  • [Cites] Oncogene. 2004 Jul 8;23(31):5378-86 [15077173.001]
  • [Cites] Tohoku J Exp Med. 1989 Jan;157(1):1-11 [2711372.001]
  • [Cites] Nature. 1997 Aug 7;388(6642):548-54 [9252186.001]
  • [Cites] Cell. 1998 May 29;93(5):875-84 [9630230.001]
  • [Cites] J Biol Chem. 1999 May 28;274(22):15297-300 [10336413.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17402-5 [10364167.001]
  • [Cites] Science. 1999 Sep 17;285(5435):1920-3 [10489373.001]
  • [Cites] IUBMB Life. 2005 Feb;57(2):83-91 [16036567.001]
  • [Cites] J Biol Chem. 2005 Aug 19;280(33):29653-60 [15975923.001]
  • [Cites] Annu Rev Microbiol. 2005;59:69-89 [15847602.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):35974-82 [16126728.001]
  • [Cites] Science. 2006 May 26;312(5777):1211-4 [16728640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18574-9 [17116858.001]
  • [Cites] Cell. 2000 Oct 13;103(2):351-61 [11057907.001]
  • (PMID = 18223255.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI 056404; United States / NIDDK NIH HHS / DK / R21 DK 072134
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Gene Products, tax; 0 / HSP90 Heat-Shock Proteins; 0 / Multiprotein Complexes; 0 / NF-kappa B; 0 / Recombinant Proteins; 0 / YopP protein, Yersinia; EC 2.7.11.10 / I-kappa B Kinase; EC 3.1.3.16 / Phosphoprotein Phosphatases
  • [Other-IDs] NLM/ PMC2397464
  •  go-up   go-down


72. Chiba K, Hashino S, Izumiyama K, Toyoshima N, Suzuki S, Kurosawa M, Asaka M: Multiple osteolytic bone lesions with high serum levels of interleukin-6 and CCL chemokines in a patient with adult T cell leukemia. Int J Lab Hematol; 2009 Jun;31(3):368-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple osteolytic bone lesions with high serum levels of interleukin-6 and CCL chemokines in a patient with adult T cell leukemia.
  • A 37-year-old woman was diagnosed as having chronic adult T-cell leukemia (ATL) of the skin by a skin biopsy and human T-cell leukemia virus type-1 serology at our hospital in August 1992.
  • The skin lesions of ATL were improved by treatment with psoralen ultraviolet ray A.
  • [MeSH-major] Chemokines / blood. Interleukin-6 / blood. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / complications. Osteolysis / blood. Osteolysis / etiology
  • [MeSH-minor] Adult. Chronic Disease. Fatal Outcome. Female. Humans

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18177436.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokines; 0 / Interleukin-6
  •  go-up   go-down


73. Haferlach T, Kohlmann A, Schnittger S, Dugas M, Hiddemann W, Kern W, Schoch C: Global approach to the diagnosis of leukemia using gene expression profiling. Blood; 2005 Aug 15;106(4):1189-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global approach to the diagnosis of leukemia using gene expression profiling.
  • Accurate diagnosis and classification of leukemias are the bases for the appropriate management of patients.
  • We analyzed gene expression profiles in 937 bone marrow and peripheral blood samples from 892 patients with all clinically relevant leukemia subtypes and from 45 nonleukemic controls by U133A and U133B GeneChip arrays.
  • In particular, acute myeloid leukemia (AML) with t(15;17), AML with t(8;21), AML with inv(16), chronic lymphatic leukemia (CLL), and pro-B-cell acute lymphoblastic leukemia (pro-B-ALL) with t(11q23) were classified with 100% sensitivity and 100% specificity.
  • Gene expression profiling can predict all clinically relevant subentities of leukemia with high accuracy.
  • [MeSH-major] Gene Expression Profiling. Leukemia / diagnosis. Molecular Diagnostic Techniques / standards
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cluster Analysis. Humans. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878973.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


74. Yamakura M, Araki K, Kimura S, Odawara J, Aoki T, Takeuchi M, Matsue K: Use of urine cytology in the diagnosis of genitourinary relapse of acute promyelocytic leukemia after allogenic stem cell transplant. Int J Hematol; 2008 Oct;88(3):251-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of urine cytology in the diagnosis of genitourinary relapse of acute promyelocytic leukemia after allogenic stem cell transplant.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / pathology. Leukemia, Promyelocytic, Acute / urine. Stem Cell Transplantation. Urine / cytology. Urogenital Neoplasms / pathology. Urogenital Neoplasms / urine
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807121.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Fan J, Ma G, Nosaka K, Tanabe J, Satou Y, Koito A, Wain-Hobson S, Vartanian JP, Matsuoka M: APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo. J Virol; 2010 Jul;84(14):7278-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo.
  • Human T-cell leukemia virus type 1 (HTLV-1) induces cell proliferation after infection, leading to efficient transmission by cell-to-cell contact.
  • After a long latent period, a fraction of carriers develop adult T-cell leukemia (ATL).
  • Genetic changes in the tax gene in ATL cells were reported in about 10% of ATL cases.
  • To determine genetic changes that may occur throughout the provirus, we determined the entire sequence of the HTLV-1 provirus in 60 ATL cases.
  • Abortive genetic changes, including deletions, insertions, and nonsense mutations, were frequent in all viral genes except the HBZ gene, which is transcribed from the minus strand of the virus.
  • G-to-A base substitutions were the most frequent mutations in ATL cells.
  • The sequence context of G-to-A mutations was in accordance with the preferred target sequence of human APOBEC3G (hA3G).
  • The target sequences of hA3G were less frequent in the plus strand of the HBZ coding region than in other coding regions of the HTLV-1 provirus.
  • HTLV-1-infected cells likely take advantage of hA3G to escape from the host immune system by losing expression of viral proteins.
  • [MeSH-major] Cytidine Deaminase / metabolism. Genome, Viral. HTLV-I Infections / virology. Human T-lymphotropic virus 1 / genetics. Leukemia-Lymphoma, Adult T-Cell / virology. Mutation. Proviruses / genetics
  • [MeSH-minor] Base Sequence. Cell Line. Genes, Reporter. Genetic Variation. Genetic Vectors. Humans. Molecular Sequence Data. Mutagenesis

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • HAL archives ouvertes. Full text from .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Oct;74(20):9525-31 [11000222.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1061-5 [15718460.001]
  • [Cites] Virus Genes. 2001;23(2):123-35 [11724264.001]
  • [Cites] J Virol. 2002 Sep;76(18):9389-97 [12186921.001]
  • [Cites] Virology. 2005 Mar 15;333(2):374-86 [15721369.001]
  • [Cites] Nat Immunol. 2005 Jul;6(7):655-61 [15970938.001]
  • [Cites] Retrovirology. 2005;2:17 [15743526.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] Retrovirology. 2005;2:32 [15943885.001]
  • [Cites] J Gen Virol. 2005 Sep;86(Pt 9):2489-94 [16099907.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6005-15 [16155607.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):381-7 [16052518.001]
  • [Cites] Retrovirology. 2005;2:64 [16242045.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):720-5 [16407133.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] EMBO J. 2006 Apr 19;25(8):1741-52 [16601696.001]
  • [Cites] J Virol. 2006 Nov;80(21):10683-91 [16943297.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2915-20 [17299050.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Nat Med. 2007 Apr;13(4):470-6 [17401375.001]
  • [Cites] J Virol. 2007 May;81(9):4422-8 [17287279.001]
  • [Cites] J Virol. 2007 Jun;81(11):5714-23 [17344291.001]
  • [Cites] Annu Rev Immunol. 2008;26:317-53 [18304004.001]
  • [Cites] Cell Host Microbe. 2008 Jun 12;3(6):388-98 [18541215.001]
  • [Cites] J Virol. 2008 Sep;82(17):8442-55 [18596104.001]
  • [Cites] J Virol. 2008 Oct;82(19):9359-68 [18653454.001]
  • [Cites] J Virol. 2002 Dec;76(24):12813-22 [12438606.001]
  • [Cites] Nat Med. 2003 Nov;9(11):1404-7 [14528300.001]
  • [Cites] Science. 2003 Nov 7;302(5647):1056-60 [14564014.001]
  • [Cites] Int J Hematol. 2003 Nov;78(4):280-96 [14686485.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):559-67 [14991578.001]
  • [Cites] Nat Struct Mol Biol. 2004 May;11(5):435-42 [15098018.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2451-8 [15152192.001]
  • [Cites] EMBO Rep. 2004 Jul;5(7):679-80 [15229643.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33177-84 [15159405.001]
  • [Cites] Curr Biol. 2004 Aug 10;14(15):1385-91 [15296757.001]
  • [Cites] J Virol. 2004 Nov;78(21):11841-52 [15479826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 May;86(9):3351-5 [2541443.001]
  • [Cites] Int Immunol. 1991 Aug;3(8):761-7 [1911545.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 [7862633.001]
  • [Cites] J Virol. 1995 Apr;69(4):2611-6 [7884912.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4243-9 [7492783.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3065-73 [8874205.001]
  • [Cites] J Neurovirol. 1995 Sep;1(3-4):286-94 [9222367.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4862-7 [9354450.001]
  • [Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]
  • [Cites] Nat Rev Immunol. 2004 Nov;4(11):868-77 [15516966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):63-8 [15623561.001]
  • [Cites] Blood. 2001 Feb 15;97(4):987-93 [11159527.001]
  • (PMID = 20463074.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / APOBEC3G protein, human; EC 3.5.4.5 / Cytidine Deaminase
  • [Other-IDs] NLM/ PMC2898234
  •  go-up   go-down


76. Mizobe T, Tsukada J, Higashi T, Mouri F, Matsuura A, Tanikawa R, Minami Y, Yoshida Y, Tanaka Y: Constitutive association of MyD88 to IRAK in HTLV-I-transformed T cells. Exp Hematol; 2007 Dec;35(12):1812-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutive association of MyD88 to IRAK in HTLV-I-transformed T cells.
  • OBJECTIVE: Constitutive activation of nuclear factor (NF)-kappaB is a common feature of human T-cell leukemia virus type I (HTLV-I)-transformed T cells.
  • Inhibition of NF-kappaB activity reduces cell growth and induces apoptosis of HTLV-I-transformed T cells, suggesting a central role of NF-kappaB in their proliferation and survival.
  • In this study, we investigated whether MyD88, an adaptor protein of Toll-like receptor (TLR) signaling, contributes to constitutive NF-kappaB activation in HTLV-I-transformed T cells.
  • MATERIALS AND METHODS: Activation status of MyD88 and interleukin (IL)-1R-associated kinase 1 (IRAK1) in HTLV-I-transformed human T cells, MT2, MT4, and HUT102 was examined by using Western blot and immunoprecipitation.
  • An expression vector encoding a dominant negative MyD88 with a deletion of its death domain (MyD88dn) was transfected into MT2 cells to evaluate roles of MyD88 in spontaneous activation of cytokine gene promoters and transcription factors, proliferation, and apoptosis in HTLV-I-transformed T cells.
  • RESULTS: Constitutive association of MyD88 with IRAK1 was observed in all three of HTLV-I-transformed T cells, but not in HTLV-I-negative T cells, such as Jurkat, HUT78, and MOLT4.
  • HTLV-I Tax enhanced TLR expression and synergistically activated NF-kappaB with wild-type MyD88.
  • CONCLUSION: Our results show a novel pathway in NF-kappaB activation in HTLV-I-transformed T cells and further demonstrate a critical role of MyD88 in their dysregulated gene activation, survival, and proliferation.
  • [MeSH-major] Human T-lymphotropic virus 1 / physiology. Interleukin-1 Receptor-Associated Kinases / metabolism. Myeloid Differentiation Factor 88 / metabolism
  • [MeSH-minor] Base Sequence. Cell Line, Transformed. Cell Transformation, Viral. DNA Primers. Humans. Protein Binding. Reverse Transcriptase Polymerase Chain Reaction. T-Lymphocytes / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17920759.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / MYD88 protein, human; 0 / Myeloid Differentiation Factor 88; EC 2.7.11.1 / Interleukin-1 Receptor-Associated Kinases
  •  go-up   go-down


77. Xavier SG, Gadelha T, Pimenta G, Eugenio AM, Ribeiro DD, Gomes FM, Bonamino M, Zalcberg IR, Spector N: JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci; 2010 Jun;55(6):1770-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the diagnosis of a myeloproliferative neoplasm in these patients is often problematic, and more objective criteria are needed.
  • METHODS: A consecutive series of 108 adult patients with portal vein thrombosis (n = 77) and Budd-Chiari syndrome (n = 31) referred for hemostasis evaluation was retrospectively studied, with a median follow-up of 51 months (1-104).
  • JAK2V617F was present in all four patients with a previous diagnosis of a myeloproliferative neoplasm.
  • In nine JAK2V617F-positive patients, the diagnosis of a myeloproliferative neoplasm was made at the thrombosis work-up, during follow-up or after JAK2V617F detection.
  • [MeSH-minor] Adolescent. Adult. Aged. Brazil. Chi-Square Distribution. Female. Gene Frequency. Genetic Predisposition to Disease. Genetic Testing. Humans. Male. Middle Aged. Phenotype. Predictive Value of Tests. Retrospective Studies. Risk Assessment. Risk Factors. Splanchnic Circulation / genetics. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2006 Jun;130(7):2031-8 [16762626.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2162-8 [15920007.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4030-6 [17712047.001]
  • [Cites] Br J Haematol. 2005 May;129(4):553-60 [15877740.001]
  • [Cites] Mayo Clin Proc. 2008 Apr;83(4):457-9 [18380991.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] Lancet. 1999 Apr 3;353(9159):1167-73 [10209995.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4272-90 [12393615.001]
  • [Cites] Eur J Haematol. 2006 Jul;77(1):57-60 [16827884.001]
  • [Cites] Nucleic Acids Res. 1989 Apr 11;17(7):2503-16 [2785681.001]
  • [Cites] J Thromb Haemost. 2007 Jan;5(1):55-61 [17059429.001]
  • [Cites] Klin Wochenschr. 1989 Aug 17;67(16):818-25 [2796252.001]
  • [Cites] Hepatology. 2005 Mar;41(3):603-8 [15726653.001]
  • [Cites] Int J Lab Hematol. 2008 Oct;30(5):415-9 [19046316.001]
  • [Cites] Hum Pathol. 2008 Jun;39(6):795-810 [18538168.001]
  • [Cites] Semin Thromb Hemost. 1997;23(5):411-8 [9387199.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1092-7 [17488875.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1299-307 [18496562.001]
  • [Cites] Semin Liver Dis. 2002 Feb;22(1):5-14 [11928075.001]
  • [Cites] Hepatology. 2000 Mar;31(3):587-91 [10706547.001]
  • [Cites] Blood. 2009 May 21;113(21):5246-9 [19293426.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2364-8 [11001884.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):736-43 [17439832.001]
  • [Cites] Hepatology. 2006 Dec;44(6):1528-34 [17133457.001]
  • [Cites] Ann Hematol. 1999 Dec;78(12):539-43 [10647877.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Dig Dis Sci. 2008 Oct;53(10):2778-83 [18343999.001]
  • [Cites] Semin Liver Dis. 2008 Aug;28(3):293-301 [18814082.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Blood Coagul Fibrinolysis. 2008 Jul;19(5):468-9 [18600104.001]
  • [Cites] Blood. 2008 May 15;111(10):4922-9 [18250227.001]
  • [Cites] J Thromb Haemost. 2007 Aug;5(8):1784-5 [17488346.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4214-22 [16484586.001]
  • [Cites] Hepatology. 2007 Mar;45(3):831-2; author reply 832-3 [17326212.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2224-32 [15710945.001]
  • [Cites] Leukemia. 2008 Nov;22(11):2020-8 [18800144.001]
  • [Cites] J Thromb Haemost. 2007 Apr;5(4):708-14 [17263783.001]
  • [Cites] J Med Genet. 2007 Jun;44(6):412-6 [17307838.001]
  • [Cites] J Thromb Haemost. 2007 Apr;5(4):859-61 [17403204.001]
  • [Cites] Haematologica. 2007 Feb;92(2):285-6 [17296594.001]
  • [Cites] Intern Emerg Med. 2008 Sep;3(3):213-8 [18274708.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3223-4 [17057021.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2452-66 [17151367.001]
  • (PMID = 19690956.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


78. Park CW, Kim A, Cha SW, Jung SH, Yang HW, Lee YJ, Lee HIe, Kim SH, Kim YH: A case of phlegmonous gastritis associated with marked gastric distension. Gut Liver; 2010 Sep;4(3):415-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of phlegmonous gastritis associated with marked gastric distension.
  • Phlegmonous gastritis is an acute and severe infectious disease that is occasionally fatal if the diagnosis is delayed.
  • Alcohol consumption, an immunocompromised state (e.g., due to HIV infection, rheumatoid arthritis, diabetes mellitus, or adult T-cell lymphoma), and mucosal injury of the stomach are reported to be predisposing factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20981225.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2956360
  • [Keywords] NOTNLM ; Gastric outlet obstruction / Phlegmonous gastritis
  •  go-up   go-down


79. Arisawa K, Soda M, Ono M, Uemura H, Hiyoshi M, Suyama A: Trends of incidence rate of adult T-cell leukemia/lymphoma in an HTLV-1 endemic area in Japan. Int J Cancer; 2009 Aug 1;125(3):737-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends of incidence rate of adult T-cell leukemia/lymphoma in an HTLV-1 endemic area in Japan.
  • [MeSH-major] Endemic Diseases. HTLV-I Infections / epidemiology. Leukemia-Lymphoma, Adult T-Cell / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Female. Humans. Incidence. Japan / epidemiology. Male. Middle Aged. Odds Ratio. Registries. Risk Assessment. Risk Factors. Time Factors

  • [Email] Email this result item
    Email the results to the following email address: